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Abstract 
 
Isoprenoids are the largest family of biologically active compounds, synthesized 
by five carbon subunits namely isopentenyl pyrophosphate (IPP) and dimethylallyl 
pyrophosphate (DMAPP). For long time the mevalonate-dependent (MVA) pathway has 
been considered as the sole source of IPP and DMAPP, until recently a new non-
mevalonte dependent (NMVA) pathway was discovered. This new pathway utilizes 
entirely different set of enzymes for isoprenoids synthesis and don’t have any 
homologues in humans. NMVA pathway is the only source of isoprenoids for certain 
eubacteria, parasite and plants. Absence of the NMVA pathway in higher organisms has 
opened a new platform for the development of novel antibiotics and antimalarials. 
 
1-deoxy-D-xylulose-5-phosphate synthase (DXS), the first enzyme in NMVA 
pathway has been reported as the rate limiting enzyme in the synthesis of IPP and 
DMAPP and has been the center of interest for inhibitor development. Reaction 
mechanism of thiamine pyrophosphate (TPP) and Mg
2+ 
dependent DXS enzyme has been 
studied in this report. Using steady state kinetics analysis, product inhibition and dead 
end inhibitor, the mechanism of substrate (pyruvate and D-glyceraldehyde-3-phosphate) 
addition was studied. Due to different domain organization in DXS as compared to the 
xi 
 
other TPP dependent enzyme, the mechanism of addition was found to be random 
sequential rather than ping-pong mechanism.  
 
Based on bioinformatics tool and in vitro studies it has been established that 
NMVA exists in all the plasmodium species, thus making the enzymes involved in 
NMVA as an alluring target for new antimalarial drugs. All the plasmodium species and 
other member of the phylum apicomplexa harbor apicoplast an organelle which is 
homologous to the chloroplast of plants and algae. All the enzymes from NMVA 
pathway translocate to apicoplast from nucleus through a secretory pathway using 
signaling and transit peptide.  In this study DXS from P. vivax has been cloned and 
expressed in E. coli using genomic DNA and codon optimized synthetic DNA as a 
source. Expression of full length DXS with signal and transit peptide as well as mature 
protein without these peptide using serial deletion has been studied. Kinetic parameters of 
P.vivax DXS have been calculated and found to be comparable to the DXS from other 
species.  
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Chapter 1: Introduction 
 
1. Introduction 
 
1.1 Isoprenoids biological relevance and its characterization 
 
Isoprenoids (or terpenoids) belongs to the largest family of small and complex 
biologically active compounds, widespread throughout the living system. Isoprene a C5 
carbon skelton (methylbuta-1, 3-diene) that is the precursor of all the isoprenoids through 
cyclization, rearrangement, and oxidation. They have diverse biological roles, 
functioning as pigments, plants hormones, vitamins (A, D, E and K), sterols, carotenoids, 
chlorophyll, components of the cell membrane and intermediate in the biosynthesis of 
glycoproteins and glycolipids (Sacchettini and Poulter 1997). Isoprene itself is not used 
for the production of isoprenoids in vivo; instead, the biological forms of isoprene are two 
branched phosphorylated five carbon precursors namely isopentyl pyrophosphate (IPP) 
and dimethylallyl pyrophosphate (DMAPP) (Figure 1.1). 
 
 
 
 
Figure 1.1: The Isoprenoids Precursors: Isopentyl Pyrophosphate (A), Dimethylallyl 
Pyrophosphate (B). 
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The library of known isoprenoids seems to increase daily as we expand our 
knowledge of natural products. List of some of the important isopenoids and their role is 
listed below: 
Table 1.1: Examples of some biologically important isoprenoids. 
Isoprenoids Importance or Role 
 Precursor of geraniol 
required for terpenes 
biosynthesis.  
 Intermediate in the HMG-
CoA reductase pathway 
used for the biosynthesis 
of terpenes, sterols. 
 Required for cell 
membrane fluidity and 
precursor of bile acids, 
steroid hormones and 
vitamin D.  
 
Antioxidant to reduce the 
production of reaction 
oxygen species formation 
during lipid oxidation. 
O
OH
vitamin E
P
O
O
O
O
OP
O
O
Geranyl pyrophosphate
HO
H
H
H
Cholesterol
P
O
O
O O
O
P
O
O
Farnesyl pyrophosphate
3 
 
 Part of the electron 
transport chain for cellular 
respiration.  
 Plant hormone required for 
development processes. 
 Form of vitamin A, 
required for vision. 
 Cyclic terpene used in 
cosmetic industry for 
citrus flavor.  
 
Isoprenoids has been classified under six major categories: 
 
1. Monoterpenoids: They contain two isoprene units linked in a head to tail fashion. 
These are the major component of the fragrant oil from leaves, flowers, and fruits 
(e.g. limonene and nerol) 
 
2. Sesquiterpenoids: These terpenoids consists of three isoprene units to form 15 
carbon   cyclic and acyclic compounds (e.g. Farnesol, Abscisic acid) 
O
O
CH3O
O
H3C
H3C
H
CH3
6-10
Ubiquinone
O
OH
O
OH
Abscisic acid
Limonene
Retinol
CH3
H3C CH3
OH
CH3CH3
4 
 
 
3. Diterpenoids: These compounds comprised of 20 carbon atom derived from 
geranyl geranoil pyrophosphate (a 10 carbon unit). Some of the important and 
well characterized diterpenes include retinol (vitamin A), the phytohormone 
gibberllin, tetrahydrocannabinol. 
 
4. Sesterterpenoids: These are derived from 25 carbon framework geranyl-farnesol 
pyrophosphate (a 10 and 15 carbon unit respectively). An example ophiobolin A, 
a fungal metabolite. 
 
5. Triterpenoids: These are the largest group of natural isoprenoid consisting of six 
isoprenoids units and include sterols such as cholesterol and lanosterol. Squalene 
being the precursor of all triterpenoids. 
 
6. Cartenoids: These consist of eight isoprenoid units to make C40 chains with 
conjugated double bonds. These function in photosynthesis because of their 
efficient light absorption properties and also prevent photo-oxidative damage in 
the cell.  Examples include lycopene and α-, β-, and γ-carotene. 
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1.2 Mevalonate Pathway for isoprenoid synthesis 
The mevalonate-dependent (MVA) pathway of isoprenoids biosynthesis has 
dominated research in this area for more than 5 decades as this pathway was considered 
as the only route to IPP and DMAPP in living systems. Interest in the MVA pathway has 
always been high due to its connection to cholesterol biosynthesis. Three Nobel Prizes 
have been awarded for understanding the structure, biosynthesis, and homeostasis of 
cholesterol: (A. Windaus in 1928, K. Bloch and F. Lynen in 1964, M. Brown and J. 
Goldstein in 1985). Pioneering work by K. Bloch and D. Rittenburg (1942) showed that 
cholesterol ring and side chains were labeled with deuterium when cells were feed with 
deuterium labeled acetate (Bloch and Rittenberg 1942), and in 1956, Folker and group 
showed that it’s the IPP unit which is the direct precursor of the cholesterol and not the 
acetate (Tavormina, Gibbs and Huff 1956). In late 1980’ M. Brown and J. Goldstein 
provided an elegant explanation of feedback regulation of cholesterol biosynthesis and its 
removal from plasma based in low density lipoprotein (LDL) receptor (Brown and 
Goldstein 1986).  
 
Mevalonate is the most important intermediate in the bioconversion of acetyl-
CoA to IPP and DMAPP (Figure 1.2).  IPP and DMAPP, to a lesser extent, are then used 
for the biosynthesis of cholesterol and other isoprenoids.  The first step of the MVA 
pathway involves the condensation of acetyl-CoA and acetoacetyl-CoA to form 3-
hydroxy-3-methlglutaryl-CoA (HMG-CoA), a reaction catalyzed by HMG-CoA synthase 
(HMGS). The next step involves HMG-CoA reductase (HMGR) catalyzed irreversible 
6 
 
reduction of HMG-CoA to mevalonate, the first committed step in isoprenoid 
biosynthesis. Mevalonate is phosphorylated in two steps to yield mevalonate-5-
diphosphate which is subsequently decarboxylated in an ATP-dependant step to yield 
IPP, phosphate, and CO2.   IPP is the exclusion product from mevalonate via the MVA 
pathway and is enzymatically converted to DMAPP by isopentenyl diphosphate 
isomerase. 
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Figure 1.2.  The Mevalonate-Dependant Production of IPP and DMAPP (A) and the 
Subsequent Conversion of IPP and DMAPP to Cholesterol (B).   The condensation of 
acetoacetyl-CoA and acetyl-CoA catalyzed by HMG-CoA synthase (HMGS) (enzyme 1).  
The NADPH-dependent reduction of HMG-CoA to mevalonate by HMGR (enzyme 2).  
Phosphorylation mevalonate at the 5-hydroxyl as catalyzed by mevalonate kinase (MK) 
(enzyme 3).  Formation of the 5-pyrophosphate catalyzed by phosphomevalonate kinase 
(PMP) (enzyme 4). The reaction of pyrophosphomevalonate decarboxylase (DMPD) to 
form IPP (enzyme 5), and the isomerization of IPP to DMAPP catalyzed by isopentenyl 
pyrophosphate isomerase (IDI) (enzyme 6).  For cholesterol synthesis (B): condensation 
of IPP and DMAPP yield geranyl pyrophosphate, which undergoes addition of an 
additional IPP to form the 15 carbon intermediate, farnesyl pyrophosphate. Reductive 
addition of two molecule of farnesyl pyrophosphate molecules leades squalene, which 
undergoes NADPH mediated reduction to form lanosterol, followed by a multistep 
transformation to cholesterol. 
 
Squalene, a C30 intermediate in the cholesterol biosynthetic pathway, is ultimately 
synthesized from six molecules of IPP; included as an example of the further metabolic 
elaboration of IPP and DMAPP (Figure 1.2) (Karl 2004). 
 
High serum cholesterol correlates to high blood pressure and a greater risk for 
cardiovascular disease and stroke (Grundy et al. 1998).  One significant outcome from 
our understanding of the MVA pathway leading to cholesterol is the development of safe 
and effective drugs to lower serum cholesterol level by inhibiting the synthesis of MVA 
pathway (Endo 1992). This is accomplished by the therapeutical use of HMGR inhibitors, 
a class of drugs known as the statins.  Early work from the Endo group led to the 
isolation of mevastatin from Penicillium citrinum as potent inhibitors of HMGR (Endo, 
Kuroda and Tanzawa 1976).  Later, a group in Merck isolated lovastatin from Aspergillus 
terreus, structurally similar to mevastatin, but more a potent HMGR inhibitor (Ki = 1.0 
nM) (Alberts et al. 1980). Currently there are several statins available in the market for 
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the treatment of high cholesterol and generate highest revenue as pharmaceutical drug 
((atorvastatin (Lipitor), fluvastatin (Lescol), lovastatin (Mevacor), and pravastatin 
(Pravachol)). 
 
1.3 Non-Mevalonate Pathway for isoprenoid synthesis 
 
Pioneering work by Rohmer and his coworker led to the discovery of the non-
mevalonate (NMVA) pathway for the biosynthesis of IPP and DMAPP derived 
isoprenoids (Rohmer et al. 1993). They studied the incorporation of universally 
13
C 
labeled glucose [U-
13
C6] in hapnoid of Rhodopseudomonas palustris and 
Rhodopseudomonas acidophila, an equivalent of cholesterol for bacteria to maintains the 
cell fluidity (Flesch and Rohmer 1988). They found that the labeling was not consistent 
with MVA pathway, and it consists of three carbon atoms from [U-
13
C6] glucose rather 
than two carbon atoms from acetate, a precursor of mevalonate (Figure 1.3).  
 
Definitive proof of the involvement of pyruvate and glyceraldehyde-3-phosphate 
(GLP) was done using 
13
C labeled pyruvate and 
13
C labeled glycerol (Rohmer et al. 
1996), mutant of E. coli defective in triose phosphate metabolism were chosen to avoid 
the inter-conversion of pyruvate and glycerol. When E. coli was incubated with 
13
C 
labeled pyruvate and unlabeled glycerol, all the mutants were found to have labeled C2 
subunit of isoprenoid, while none of the 
13
C glycerol was incorporated in C2 subunit of 
9 
 
isoprenoid skeleton when E. coli was culture in 
13
C labeled glycerol and unlabeled 
pyruvate. While, C3 subunit of isoprenoid was only incorporated form 
13
C pyruvate with 
E. coli defective in glycerol kinase, glycerol phosphate dehydrogenase, triose phosphate 
isomerase mutants and from 
13
C glycerol with enolase, phosphoglycerate kinase and 
glyceraldehyde phosphate dehydrogenase defective mutants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: (A) Labeling pattern of Glyceraldehyde-3-phosphate (GLP), Pyruvate and 
Acetyl-CoenzymeA starting from labeled glucose during glycolysis and pyruvate 
dehydrogenase reaction, (B) labeling pattern in IPP synthesis by mevalonate pathway 
using acetyl-coA, (C) labeling pattern in IPP synthesis by non-mevalonate pathway using 
GLP and pyruvate. 
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In another attempt to prove that mevalonate is not the precursor for the 
isoprenoids in certain eubacteria and plants, E. coli. was incubate with [2-
13
C], [2,3-
13
C
2
] 
and [2,4-
13
C2]-1-d-deoxyxylulose and its integration into the ubiquinone suggested that 
an alternate pathway for exists for IPP synthesis (Putra et al. 1998). These experiments 
pointed GLP as the only precursor of the C3 subunit in isoprenoid skeleton. 
 
There are more than 20,000 plants terpenes have been reported and the origin has 
always been associated with MVA pathway. While, study done by Arigoni and Schwarz 
in Ginkgo biloba (maidenhair tree) showed that higher plants have both MVA and 
NMVA pathways and separated by compartmentalization (Eisenreich et al. 1998). Higher 
plants have an unusual balance for the terpenoids synthesis through both MVA and 
NMVA pathways. It has been shown that sterols and ubiquinone is biosynthesized by 
MVA pathway, while variety of monoterpenes and diterpenes such a menthone, thymol, 
geraniol, THC, β-carotene, lutein, etc. are synthesized by NMVA pathway.  
 
  Assignment of MVA and NMVA pathways to bacteria, archaea, plants, fungi 
and animal was been done using genome mining. All the genes of MVA pathway were 
known before the whole genome sequence were published, and were later used as a 
template to assign the pathway utilized for isoprenoid synthesis. In case of NMVA 
pathway, the first two enzymes (DXS and DXR) sequence were known by the end of the 
last century and later used as a template to find the prospective orthologs in the genome 
database (Gräwert et al. 2011). Since 1990, NMVA pathway has been explored in to a 
11 
 
great extent and genome mining through search of open reading frame has leads to the 
elucidation of all the enzymes involved in this pathway. Plethora of information from this 
new mechanism of isoprenoid synthesis can be used to develop new family of antibiotics, 
herbicides, etc. Another great opportunity for the better life of mankind can be achieved 
by targeting Plasmodium falciparum parasite, responsible for Malaria. This pathway 
presents an analogy to the MVA pathway, where targeting the HMGR has leads to the 
development of cholesterol lowering drugs. All the seven enzymes involved in this 
pathway will be discussed in detail in here: 
 
1. 1-deoxy-D-xylulose-5-phosphate synthase (DXS): This enzyme catalyzes the 
thiamine and Mg
2+
 dependent condensation of pyruvate and GLP to from 1-deoxy-D-
xylulose-5-phosphate (Figure 1.4) (Lange et al. 1998, Eisenreich et al. 1998). DXS (EC 
2.2.1.7) belongs to the family of enzymes which uses thiamine pyrophosphate (TPP) as a 
co-factor and shares a high homology with pyruvate dehydrogenase (EC 1.2.4.1), 
pyruvate decarboxylase (EC 4.1.1.1), and transketolase (EC 2.2.1.1). To understand the 
role of DXS as a rate limiting enzyme a transgenic Arabidopsis thaliana was constructed 
to over and under express this enzyme (Estévez et al. 2001). The effect of expression on 
chlorophyll, α-tocopherol, carotenoids, abscisic acid was studied. This study clearly 
showed that the transgenic A. thailiana expressing higher amount of DXS showed 
elevated level of isoprenoids under observation and reduced level for lower expressing 
DXS as compared to wild type, which suggest DXS as the committed and rate limiting 
enzyme in NMVA pathway.   
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Figure 1.4: Reaction catalyzed by DXS 
 
2. 1-deoxy-D-xylulose-5-phosphate reductoisomerase (DXR): This enzyme (EC 
1.1.1.267) catalyzes the NADPH and Mg
2+
/Mn
2+
 dependent conversion of 1-deoxy-D-
xylulose-5-phosphate (DXP) to 2C-Methyl-D-erythritol-4-phosphate (MEP) (Figure 1.5).  
This step involves the rearrangement and two electron reduction of linear carbon skeleton 
to branched chain isoprenoid precursor, shown by the heavy isotope labeling study 
(Reuter et al. 2002). DXR has been cloned, over expressed and crystallized from many 
organisms including E. coli. (Steinbacher et al. 2003), M. tuberculosis (Henriksson et al. 
2007), and Z. mobilis (Ricagno et al. 2004). Crystal structure of DXR shows that each 
subunit of the homodimer consists of N-terminal NADPH binding domain connected 
with active domain pocket. Great detail of mechanistic study has been performed for E. 
coli DXR (Fox and Poulter 2005, Koppisch et al. 2001), using fosmidomycin and 
dihydro-NADPH as a dead end inhibitor to show that DXR undergoes an ordered 
sequential mechanism with NADPH binds before DXP. 
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Figure 1.5: Reaction catalyzed by DXR 
 
 
3. 4-Diphosphocytidyl-2C-methyl-D-erythritol 4-phosphate synthase (IspD): IspD 
(EC 2.7.7.60) is the third enzyme in the NMVA pathway catalyzing the formation of 4-
diphosphocytidyl-2-C-methylerythritol (CDP-ME) from MEP and cytidyl triphosphate 
(CTP) (Figure 1.6). Discovery of IspD represents an example of advancement in 
biochemical and comparative genomic analysis. In order to search for the subsequent 
enzyme that utilizes MEP as substrate, E. coli crude cell lysate was incubated with MEP 
led to the conversion to CDP-ME by reaction with CTP, a preferred nucleotide 
triphosphate over ATP, UTP and GTP (Richard et al. 2001).  
 
The crystal structure of IspD from E. coli with substrate complex shows the 
coordination of α, β and γ phosphate of CTP with Mg2+. The possible mechanism 
includes the formation of reactive cytidyl monophosphate (CMP) upon loss of 
pyrophosphate (ppi) and subsequent reaction with 4-phosphate group of MEP to form 
CDP-ME. A recent pulse chase experiment (Richard et al. 2004), using [2-14C] MEP and 
[2-14C] CTP, it was shown that CTP binding precedes to that of MEP, which points 
towards an ordered sequential mechanism. 
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Figure 1.6: Reaction catalyzed by IspD  
 
4. 4-Diphosphocytidyl-2C-methl-D-erythritol Kinase (IspE): This enzyme (EC 
2.7.1.148) catalyzes Mg
2+
 dependent phosphorylation at 2-hydroxy position of CDP-ME 
using ATP as second substrate (Figure 1.7). IspE shares high homology with homoserine 
kinase, mevalonate kinase and phospho-mevalonate kinase (collectively called GHMP) 
(Miallau et al. 2003). Crystal structure of E. coli IspE with CDP-ME and non-
hydrolysable from of ATP displayed a α/β fold characteristic of the GHMP kinase 
superfamily. 
 
 
 
 
 
 
Figure 1.7: Reaction catalyzed by IspE 
 
5. 2C-Methyl-D-erythritol 2,4 diphosphate synthase (IspF): This enzyme (EC 
4.6.1.12) catalyzes the conversion of 4-diphosphocytidyl-2C-methyl-D-erythritol 2-
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phosphate to 2C-methyl-D-erythritol 2,4-cyclodiphosphate (cMEDP) (Figure 1.8) and 
release of cytidyl monophosphate (CMP) (Kemp, Bond and Hunter 2002). IspF from 
Plasmodium falciparum has been also shown to catalyze the conversion of CDP-ME or 
4-diphosphocytidyl-2C-methyl-D-erythritol 2-phosphate to 2-phospho-2C-methyl-D- 
erythritol 3,4-cyclic monophosphate (Figure 1.8) at lower rate (~10%) (Rohdich et al. 
2001), and it has been associated to the structural perturbation of the catalytic domain. In 
an another report Mesorhizobium loti has an open reading frame of IspD and IspF as a  
Figure 1.8: Reactions catalyzed by IspF 
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fusion protein and IspE on other part of the chromosome (Testa et al. 2006). Incubation 
of the bi-functional IspDF with MEP, CTP and ATP only yield CDP-ME and not 
cMEDP. When the same constituent were incubated with IspE then there was a formation 
of cMEDP.  
 
6. 2C-Methyl-D-erythritol 2, 4-cyclodiphosphate reductase (IspG): This enzyme (EC 
1.17.7.1) catalyzes the conversion of cMEDP to 1-hydroxy-2-methyl-2-(E)-butenyl 4-
diphosphate (Figure 1.9). Discovery of this enzyme was confirmed by recombinant 
hyper-expression of DXS, DXR, IspD, IspE and IspF in E. coli (Hecht et al. 2001). E. 
coli strain grown in media with 
13
C labeled 1-deoxy-d-xylulose (DX) led to the 
accumulation of cyclic pyrophosphate precursor. Addition of IspG gene in this system 
leads the conversion of DX to 1-hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate as 
characterized by NMR (Zepeck et al. 2005).  
 
 
 
 
 
 
 
Figure 1.9: Reaction catalyzed by IspG 
 
 
 
17 
 
7. 1-Hydroxy-2-methyl-butenyl 4-diphosphate reductase (IspH): This enzyme (EC 
1.17.1.2) catalyzes the conversion of 1-hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate to 
IPP and DMAPP (Figure 1.10). IspH was discovered using the same strategy as that for 
IspG. E. coli strain bearing all the enzyme of the NMVA pathway converted the 
13
C 
labeled DX to IPP and DMAPP. IspH possesses a redox-active [4Fe-4S]
2+
 cluster for 
radical mediated cleavage of C-OH bond (Rohdich, Bacher and Eisenreich 2004). Due to 
the sensitivity towards the oxygen (in solution and atmospheric) all the characterization 
step for IspH were performed under anaerobic conditions.    
 
 
 
 
 
 
Figure 1.10: Reaction catalyzed by IspH 
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1.4 Non-Mevalonate Pathway as a potential drug target  
 
Sequencing of human genome represents a milestone achievement by the 
scientific community. Since then the process of whole genome sequencing of various 
organisms has gone up by an astonishingly high rate. The technology in terms of 
genomics and software have advanced so much that now a day the whole genome from 
an individual takes only 1-2 weeks. There are commercial ventures (GenomeQuest, 
Complete genomics, etc.) (Roach et al. 2010), which supports the whole genome 
sequence with accuracy of 99.99% and much lower price ($1,800) as compared to the 
human genome project which costs around $4 billion. There are many aspects and 
benefits associated with genome sequencing and have been used for the better life of 
mankind. Early detection of genetic discrepancies, rational drug design, diagnosis of 
diseases, and gene therapy collectively termed as molecular medicine has revolutionized 
the field of biomedical research. Understanding anthropology and evolution through 
comparative genomics has led to the association of diseases and traits.  
 
Molecular medicines have helped the human race to overcome various diseases 
caused by bacteria, parasites and yeast infection. But, lately we have been facing an 
emerging trend in resistance against antibiotics and anti-parasitic drugs. Several of the 
last resort antibiotics such as vancomycin have been shown to non-effective against 
Staphylococcus aureus, bacteria responsible for wound and surgical infection in hospitals 
(Leeb 2004).  
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All the major pharmaceutical companies have currently stopped working on the 
development of new antibiotics because of the lower percentage of profit generated to the 
investment. These companies have shifted to the development of drugs for high 
cholesterol, rheumatoid arthritis, depression, erectile dysfunction, etc. and all the new 
antibiotics in the development in just a mere modification of old antibiotics. Tropical 
diseases such as malaria, tuberculosis, leishmaniasis, chagas, etc. are the most neglected 
human health problem. Malaria being the most profound human problems with highest 
annual morbidity and several hundred million reported cases worldwide. 
 
Malaria primarily affects people living below the poverty line and couldn’t afford 
medication. In addition to the high annual mortality, malaria causes dramatic economic 
loss, hardship due to the inability of acutely infected individuals to work and in children 
it can lead to life-long learning impairment (Breman, Egan and Keusch 2001). The 
widespread nature of P. vivax compared to P. falciparum and evidence of mounting 
resistance to current drugs in the plasmodium species makes it vital to discover and 
develop new drugs for these species. Out of the four species of the malaria parasite, the 
majority of morbidity is caused by Plasmodium falciparum and Plasmodium vivax. P. 
falciparum is the most studied species because it has the highest rate of mortality and its 
widespread resistance to anti-malarial drugs. Drugs like Chloroquine and Fansidar now 
suffer from worldwide resistance problem; this growing concern in the treatment of 
malaria is because of poor implementation of therapies, toxicity of existing therapeutics, 
and the small number of available therapeutics. 
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Molecular basis of antimalarial resistance has been cause primarily because of the 
mutation in drug target which reduces the sensitivity. Some drugs such as chloroquine 
and mefaloquine don’t have any protein targets which can mutate, these classes of drugs 
become resistant through the mutation in transporters (Woodrow and Krishna 2006). 
Elevated level of transporters such as pfmdr1 (Plasmodium falciparum multi drug 
resistant gene-1) effectively reduces the drug concentration at target site (Ruetz et al. 
1996). Arylaminoalcohol resistance is one example in which there is an elevated gene 
copy number of pfmdr 1.  Increasing drug resistance for chloroquine, mefaloquine, 
arylaminoalcohol and artemisinins in sub-saharan Africa, South Asia and America 
presents a perplexing problem which can only be solved by studying the new drug target 
in plasmodium species.  
 
Antibiotics and antimalarial drug resistance has been under study for more than 
two decades because of the high mortality associated with it. Non-mevalonate pathway as 
discussed earlier is one of the last evolutionary pathway which can be considered as an 
alternative drug target because of the non-existence in higher species. Enzymes involved 
in the synthesis of isoprenoids using NMVA pathway don’t have any orthologous in 
mammalian system. Arabdopsis thaliana and Listeria monozytogenes are some of the 
exceptions which use both the pathways for the isoprenoids synthesis. Complete genome 
sequence analysis of microbial species has found the consistence presence of NMVA 
pathway with few anomalies (Table 1.2), but the overall consensus represents this as a 
promising target. 
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Table 1.2: Distribution of metabolic enzymes involved in the biosynthesis of isoprenoids 
Organisms Non-Mevalonate Pathway Mevalonate Pathway 
DXS DXR IspD IspE IspF IspG IspH hmgs hmgr mk pmk dmpd iDiI 
Deinococcus  
radiodurans 
+ + + + + + + - - - - - - 
Escherchia 
coli 
+ + + + + + + - - - - - + 
Bacillus  
subtilis 
+ + + + + + + - - - - - - 
Mycoplasma  
genitalium 
- - - - - - - - - - - - - 
Listeria  
monozytogens 
+ + + + + + + + + + + + - 
Plasmodium  
falciparum 
+ + + + + + + - - - - - - 
Homo sapiens - - - - - - - + + + + + + 
*(+ = Presesnt, - = Absent) 
**Table adapted from Eisenreich et al (Eisenreich et al. 2004) 
 
 
All the current antibiotics work predominantly by targeting the biosynthesis of 
macromolecular component (DNA, RNA, cell wall) of bacteria cell, while few of them 
actually target the metabolic enzymes (folic acid biosynthesis). In a bioinformatics 
analysis by Arigoni et al. it was found that approximately 30 E. coli genes with 
orthologous in other bacterial species are essential for the survival (Arigoni et al. 1998). 
NMVA pathway metabolic enzymes are among these set of genes, which are found in 
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pathogenic bacteria including Mycobacterium tuberculosis and Helicobacter pylori. E. 
coli carrying the deletion of NMVA pathway genes can to be only rescued by the supply 
of exogenous mevalonate (Altincicek et al. 2001), indicating the critical requirement of 
NMVA pathway for survival. 
 
Along with bacteria some protozoal genomes e.g. Trypanosoma cruzei, 
Leishmania major, Toxoplasma gondii, Crytosporidium parvum, Plasmodium falciparum 
and Plasmodium vivax have to been shown to have orthologous of the NMVA pathway 
enzymes. A long N-terminal leader/signaling sequence have been reported to present in 
the genes from plasmodium, which is believed to target the enzymes to the apicoplast. 
Apicoplast are supposed to be derived from secondary endosymbiosis of a plastid bearing 
red algae (Yeh and DeRisi 2011). Apicoplast in plasmodium has lost its photosynthetic 
function and most of its genome is transferred to the nucleus over the course of evolution, 
and it’s function is necessary for the survival of plasmodium in intraerythrocytic and 
intrahepatic stages. It has also been shown that fosmidomycin inhibited NMVA pathway 
can be rescued by the exogenous supply of IPP and DMAPP (Yeh and DeRisi 2011). In 
summary, NMVA pathway represents a highly potential target for the development of 
novel antibiotics and antimalarial.  
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Chapter 2: 1-deoxy-D-xylulose-5-phosphate synthase (DXS) Reaction Mechanism 
 
2.1 Introduction 
 
2.1.1 Isoprenoids biosynthesis through MVA and NMVA pathways 
 
Isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP) are 
the precursor for isoprenoids, which is the largest family of biologically active 
compounds. Example of important isoprenoids include the ubiquiniones, sterols, dichols, 
triterpenes, and chlorophyll (Eisenreich et al. 1998). The isoprenoids family of molecule 
represents the most diversified set of chemical entities known to man and is of immense 
importance. Cholesterol one of the most intensly studied molecule derived from the IPP 
and DMAPP, serves as a precursors to steroids such as, the glucocorticoids, the 
androgens, the mineralocorticoids, the gestagens and estrogen (Eisenreich et al. 2004). 
The natural products Taxol, a relative recent addition to the isoprenoid family is clinical 
useful drug for treatment of mammary and ovarian tumors (Holmes et al. 1991).  
 
The biomedical importance of the isoprenoids has always intrigued the scientific 
community with question “How these molecules are synthesized in the cell?” This 
intriguing question was answered for the Cholesterol in research that spanned the 1940’s 
and the 1950’s. The conversion of acetyl-CoA to cholesterol is outlined in every standard 
31 
 
undergraduate textbook and takes place in four stages.  Stage 1 is the conversion of 3 
acetyl-CoA thioesters to CO2 and the 5-carbon acid, mevalonate (HOCH2-CH2-
COH(CH3)-CH2-COO‾).  Stage 2 is conversion of mevalonate to the activated isoprenes, 
IPP and DMAPP.  Stage 3 is the conversion of IPP and DMAPP to the linear 30-carbon 
intermediate, squalene.  The conversion of IPP and DMAPP to squalene involves the 
condensation of IPP and DMAPP to produce the 10-carbon geranyl pyrophosphate and 
pyrophosphate.  A reaction between IPP and geranyl pyrophosphate leads to farnesyl 
pyrophosphate, a 15-carbon intermediate.  Two farnesyl pyrophosphates react to generate 
the 30-carbon squalene.  Stage 4 is cyclization of squalene to a fused ring 30-carbon 
sterol which is subquently "trimmed down" to the 27-carbon cholesterol (Figure 1.2) 
(Vance and Van den Bosch 2000).  
 
For many years, it was thought that IPP, DMAPP, and all the biologically-
occuring isoprenoid were derived solely from this mevalonate-dependent (MVA) 
pathway.  Recently, an alternative pathway to IPP, DMAPP, and the isoprenoids has been 
uncovered that exists in many eubacteria, green algae, protozoa, and plants. In this 
alternative pathway, IPP is derived not from mevalonate, but from pyruvate and 
glyceraldehydes 3-phosphate.  A 5-carbon sugar phosphate, xylulose-5-phosphate is a 
key intermediate in the mevalonate-independent pathway of isoprenoid biosynthesis 
(Figure 2.1) (Rohmer et al. 1996).  The enzymes catalyzing the reactions of the 
mevalonate-independent pathway or non-mevalonate pathway (NMVA) are completely 
different than the enzymes of MVA pathway of isoprenoid biosynthesis 
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2.1.2 Targeting non-mevalonate pathway   
 
Many of the human pathogens produce their isoprenoids exclusively via the 
NMVA pathway or a combination of the MVA and NMVA pathways.  Of particular 
relevance to my research, the Plasmodium species that cause malaria are solely 
dependent upon the NMVA pathway for the production of IPP, DMAPP, and their 
isoprenoids (Cassera et al. 2004).  Thus, inhibitors to the enzymes in the Plasmodium 
NMVA pathway are likely to be quite useful to treat malaria.  
 
New treatments for malaria are essential as there has been an alarming increase in 
the rate of resistance to standard drug therapies in the last 10 years. The problem of drug 
resistance in the malaria parasite needs to be addressed before it become unsolvable. 
Most of the antimalarial and antibiotics in the market were developed more than 20 year 
ago and have merely been modified to develop more recent antimalarial drugs (Leeb 
2004, Rohdich, Bacher and Eisenreich 2004). The antimalarials predominately work by 
targeting the biosynthesis of critical macromolecules (such as DNA, RNA, and the cell 
wall) (Sahu, Sahu and Kohli 2008).  More promising drugs can be designed by targeting 
the enzymes involved in the key steps of physiological processes unique to Plasmodium 
parasite.  The enzymes of the NMVA pathway are excellent targets for the development 
of new antimalarial drug because there are no homologues to these enzymes in man and 
other mammals.  Because the NMVA pathway is solely responsible for IPP, DMAPP, 
and the isoprenoids in a number of human and animal pathogens and in problematic 
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weeds (Table 1.2), the enzymes of the NMVA pathway are intriguing targets for the 
development of novel drugs and herbicides. 
 
2.1.3 Biochemistry of non-mevalonate pathway 
 
The first committed step in the NMVA pathway (Figure 2.1) involves the 
condensation of pyruvate (Pyr) and D-glyceraldehydes-3-phosphate (D-GLP) to 1-deoxy-
D-xylulose-5-phosphate (DXP) and CO2 catalyzed by 1-deoxy-D-xylulose-5-phosphate 
synthase (DXS). Next step involves the NADPH reductive rearrangement of DXP to 2-C-
methyl-D-erythritol 4-phosphate (MEP) catalyzed by D-xylulose-5-phosphate 
reductoisomerase (DXR). In the sequential steps MEP is conjugated with cytidine 
monophosphate (CMP), followed by phosphorylation of the C2 hydroxyl group, 
elimination of CMP and cyclization to form 2C-methyl-D-erythritol 2, 4-
cyclodiphosphate. The enzymes catalyzing these reactions are IspD, IspE, IspE and IspF 
respectively. The last steps involve the formation of 1-hydroxy-2-methyl-2(E)-butenyl 4-
diphosphate (HMBPP) and then to IPP and DMAPP by IspG and IspH, respectively 
(Figure 2.1). The IspH protein catalyzes the reduction of HMBPP to IPP and DMAPP at 
ratio of ~ 6 IPP to 1 DMAPP (significantly different from the thermodynamic 
equilibrium of ~1 IPP/3 DMAPP) (Gräwert et al. 2010).  The interconversion of IPP and 
DMAPP is catalyzed by isopentenyl diphosphate isomerase (the Idi protein), which exists 
two species dependent forms, IDI-I and IDI-II (Kaneda et al. 2001, Barkley, Desai and 
Poulter 2004).  Idi may be expressed in Plasmodium and (Mohanty and Srinivasan 2009), 
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if so, is likely present in the cytoplasm as IPP alone is able to rescue apicoplast-minus 
parasites (Yeh and DeRisi 2011).   
 
 
 
 
 
 
 
 
 
 
Figure 2.1: The Non-Mevalonate Dependent Biosynthesis of IPP and DMAPP 
2.1.4 DXS a rate limiting enzyme in NMVA pathway 
 
DXS catalyzes a thiamine pyrophosphate (TPP) and divalent metal ion (Mg
2+
 or 
Mn
2+
) dependent transketolase-type condensation reaction and that is rate-limiting step in 
NMVA pathway. DXS from Rhodobacter capsulatus, Mentha x piperita, Mycobacterium 
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tuberculosis, Arabdopsis thaliana, and Escherichia coli have been studied and 
characterized (Estévez et al. 2000, Lange et al. 1998, Hahn et al. 2001, Mao et al. 2008, 
Lois et al. 1998) . DXP, the product of the DXS reaction, is not only used for the 
production of IPP, DMAPP, and the isoprenoids, but is also the biosynthetic precursor to 
thiamine (vitamin B1) and pyridoxal (vitamin B6) in Plasmodium and other species 
(Müller, Hyde and Wrenger 2010). Both the MVA and NMVA pathways exist in higher 
plants, with majority of the IPP supply in cytoplasm being produced by the MVA 
pathway, while most of the the IPP supply in the plastid coming from the NMVA 
pathway.  Up- and down-regulation of DXS expression in A. thaliana (Estévez et al. 
2000, Estévez et al. 2001) results in the commensurate changes in the level of the 
isoprenoids: up-regulation increases the cellular levels of the isoprenoids while down-
regulation suppresses the isoprenoid levels. Alteration in the expression and regulation of 
DXS in A.thaliana demonstrates that that DXS is essential for normal growth and 
provides additional evidence that DXS catalyzes the rate-limiting step in the NMVA 
pathway.   
 
Recombinant DXS has been overexpressed from many species and its crystal 
structure from Escherchia coli and Deinococcus radiodurans has been reported (Xiang et 
al. 2007). Relative to the other dimeric TPP dependent enzyme, DXS is unusual in its 
domain organization and active site location within the monomer. Monomer unit of TPP 
dependent enzymes typically consists of three domains with active site located at the 
interface between the individual monomers and domain I of one monomer is located 
above domain II and III of the other monomer. However DXS exhibits a novel domain 
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organization with active site located within a monomer and domain I of one monomer is 
located right above domain II and III of the same monomer (Figure 2.2).  
 
 
 
 
 
 
 
 
 
 
Figure 2.2: Crystal structure of DXS from D. radiodurans. This structure illustrates the 
dimer with one active site per monomer. Each active site contains a bound TPP (shown as 
red and orange colored balls). 
 
 
 
 
 
37 
 
2.1.5 DXS reaction mechanism 
 
DXS belongs to TPP dependent transketolase, pyruvate decarboxylase and 
carboligase family which uses ping-pong mechanism for catalysis, where release of the 
first product is preceded by the binding of second substrate (Figure 2.3A) (Liu et al. 
2001). A ordered sequential kinetic mechanism has been reported for Rhodobacter 
capsulatus DXS, with pyruvate binding first. D-GLP then bind to form the active DXS-
Pyr-GLP complex which is then followed by the release of CO2 and DXP in that order 
(Figure 2.3B) (Eubanks and Poulter 2003). In another report using single-molecule force 
spectroscopy (SMFS) nano sensor technique it was found that D-GLP binding was 
enhanced by 1.7-folds in the presence of pyruvate using E. coli DXS, also suggesting the 
reaction to proceed though ordered sequential mechanism (Sisquella et al. 2010). A 
recent conflicting report by Meyers and group have proposed that the reaction catalyzed 
by E. coli DXS proceeds through random sequential mechanism using tryptophan 
fluorescence quenching study (Figure 2.3C) (Brammer et al. 2011). In this study it was 
found that binding of the first substrate is independent of the binding of the second 
substrate and binding constants for pyruvate and D-GLP (individually) were calculated in 
absence of the second substrate. 
 
 
 
38 
 
 
 
 
 
 
 
 
 
Figure 2.3: Proposed mechanisms for the reaction catalyzed by DXS 
 
The focus of the present study is to comprehend the active site pocket of D.rad 
DXS using DXS mutants and elucidate the mechanism of substrate binding using steady 
state kinetic analysis, product inhibition with DXP, and a dead end inhibitor 
(fluoropyruvate, F-Pyr). This work will lead to a better understanding of the DXS-
catalyzed reaction to aid in the rational design of DXS inhibitors for the treatment of 
malaria and other human diseases. 
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2.2 Materials and Methods: 
 
2.2.1 Materials: 
 
Thiamine pyrophosphate, pyruvate, glyceraldehyde-3-phosphate, 1-deoxy-D-
xylulose-5-phosphate sodium salt, bovine serum albumin and LB-broth were purchased 
from Sigma Aldrich. NADPH was from Alexis Biochemical’s, Ni-NTA resin was from 
Invitrogen, and β-mercaptoethanol (β-Me) was from Fisher. E. coli XL-10 cells, 
deoxynucleotide mix PCR grade, pfuUltra hotstart DNA polymerase, QuikChange II site 
directed mutagenesis kit and acetonitrile (HPLC grade) were purchased from Agilent. 
The DNA vectors pET28a(+) and pET15b(+) and E. coli BL-21 B(DE3) cells were 
purchased from EMD Biosciences. DNA sequencing and primers were purchased from 
MWG Operon.  All the other reagents were of the highest quality commercially available.  
 
2.2.2 Cloning of recombinant D. radiodurans 1-deoxy-D-xylulose-5-phosphate 
synthase (DXS) and E. coli 1-deoxy-D-xylulose-5-phosphate reductoisomerase (DXR): 
 
A codon optimized synthetic D.radiodurnas dxs gene with 5’-NdeI and 3’-XhoI 
restriction sites in pMK vector was purchased from Geneart, Germany. The dxs gene was 
used to clone cloned in pET28a(+) vector ( kanamycin resistance) with N-terminal His-
tag to yield pET28a(+)-DXS plasmid. Briefly, pET 28a(+) vector and pMK vector were 
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digested with NdeI and XhoI restriction enzyme for 1 hour each at 37
o
C, followed by 
digestion of pET28a(+) with Antarctic phosphatase for 30 mins at 37
o
C. The digested 
samples were then run on an agarose gel (0.7%) and the appropriate bands were extracted 
for the overnight ligation at 16
o
C. An aliquot of the ligation reaction (4 µL) was used to 
transform E. coli XL-10 cells and plated on LB plates with kanamycin. Only colonies 
with vector pET28a(+)-DXS grew on the plate and were  cultured. Plasmid was extracted 
from the cells cultured overnight and used for primary screening to confirm the insertion 
of dxs gene in pET28a(+) vector. Cloning was further confirmed by DNA sequencing at 
MWG Operon. Codon optimized E. coli dxr gene with 5’-NdeI and 3’-BamHI restriction 
sites was used to clone in pET15b(+) with N-terminal His tag using the same protocol 
described above. 
   
2.2.3 Production of DXS mutant by site-directed mutagenesis 
 
Site directed mutagenesis was carried out using the QuikChange II site directed 
mutagenesis kit. Briefly, the mutagenesis mixture consists of 50-100 ng plasmid 
pET28a(+)-DXS as a template, 1X PCR reaction buffer, 0.4 mM each of the forward and 
reverse primer (Table 2.1), 0.25 mM dNTP mixture,  5 µL Quik solution, and 2.5 units of 
pfuUltra hotstart polymerase in a 50 µL reaction. The PCR thermo cycler settings used 
were: 95
o 
C for 4min., 18 cycles of denaturation at 95
o 
C for 30 sec., annealing at gradient 
temperature between 58-61
o 
C for 30 sec., elongation at 72
o 
C for 16 min. and one final 
elongation step at 72
o 
C for 10 min. Samples were kept at 4
o 
C, before digestion with 
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DpnI at 37
o 
C for 2 hrs. These digested reactions were stored at -80
o 
C before 
transformation of XL-10 cells. The sequence of the mutant plasmids DNA were 
confirmed by DNA sequencing. 
 
2.2.4 Production of DXS mutant using the overlap extension method 
 
The overlap extension method was used to produce the DXS mutant that were 
difficult to create via site directed mutagenesis. In this method, two PCR reactions were 
performed using set of primer in which one of set of primers possesed a point mutation 
and has an overlap (>15 base pairs) with the primer of the second PCR reaction 
(Appendix figure S-28). PCR products were extracted and used as a template for the next 
round of PCR in order to create the gene of interest with a point mutation. This product 
was ligated into pET28a(+) vector using the NdeI and XhoI restriction sites as discussed 
in section 2.2.2 and confirmed by DNA sequencing. 
Table 2.1: PCR primers used to create the DXS mutants 
Mutant Type Sequence 
E373A Sense 5’ GAT GTG GGC ATT GCG GCG GAA GTG GCG GTT ACC A 3’ 
Antisense 5’ TGG TAA CGC CCA CTT CCG CCG CAA TGC CCA CAT C 3’ 
H82A Sense 5’ TTT GAT GTG GGC GCT CAG GCG TAT GC 3’ 
Antisense 5’ GCA TAC GCC TGA GCG CCC ACA TCA AA 3’ 
H304A Sense 5’ GAT CCG ATT TAT TGG GCT GGT CCG GCG AAA TTT 3’ 
Antisense 5’ AAA TTT CGC CGG ACC AGC CCA ATA AAT CGG ATC 3’ 
Y395F Sense 5’ CGT CCG GTG GTG GCG ATT TTT AGC ACC TTT C 3’ 
Antisense 5’ GAA AGG TGC TAA AAA TCG CCA CCA CCG GAC G 3’ 
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Y395A Sense 5’ GTG GTG GCG ATT GCT AGC ACC TTT CTG CAG 3’ 
Antisense 5’ CTG CAG AAA GGT GCT AGC AAT CGC CAC CAC CGG ACG 3’ 
N181A Sense 5’ CGC AAA ATG CTG ATT GTG CTG GCC GAT AAC GAA ATG 
AGC ATT AG 3’ 
Antisense 5’ CTA ATG CTC ATT TCG TTA TCG GCC AGC ACA ATC AGC  
ATT TTG CG 3’ 
R423A Sense 5’ TCT GAA CGT GAC CTT TTG CAT TGA TGC TGC GGG CAT 
 TGT G 3’  
Antisense 5’CAC AAT GCC CGC AGC ATC AAT GCA AAA GGT CAC GTT CAG 
A 3’ 
R423K Sense 5’ ACC TTT TGC ATT GAT AAG GCG GGC ATT GTG GGT 3’ 
 Antisense 5’ ACC CAC AAT GCC CGC CTT ATC AAT GCA AAA GGT 3’ 
D430A Primer-A 5’ ATC CCA TAT GAA CGA GCT GCC GGG CAC CAG C 3’ 
Primer-B 5’ ATC CCT CGA GTT ATT ACA CTT CAA TCG G 3’ 
Primer-C 5’ TGT GGG TGC GGC TGG CGC GAC CC 3’ 
Primer-D 5’ GGG TCG CGC CAG CCG CAC CCA CA 3’ 
H434A Primer-A 5’ ATC CCA TAT GAA CGA GCT GCC GGG CAC CAG C 3’ 
Primer-B 5’ ATC CCT CGA GTT ATT ACA CTT CAA TCG G 3’ 
Primer-C 5’ GAT GGC GCG ACC GCT AAC GGC GTG TTT 3’ 
Primer-D 5’ AAA CAC GCC GTT AGC GGT CGC GCC ATC 3’ 
N183A Primer-A 5’ ATC CCA TAT GAA CGA GCT GCC GGG CAC CAG C 3’ 
Primer-B 5’ ATC CCT CGA GTT ATT ACA CTT CAA TCG G 3’ 
Primer-C 5’ GCT GAT TGT GCT GAA CGA TGC CGA AAT GAG CAT TAG 3’ 
Primer-D 5’ CGC TAA TGC TCA TTT CGG CAT CGT TCAGCA CAA TCA GC 3’ 
 
 
2.2.5 Overexpression and purification of DXS and the DXS mutants 
 
Both wild type and mutant DXS plasmid were transformed in E. coli BL-21 
B(DE3) cells and used for protein expression. An overnight culture of E. coli in LB broth 
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containing 50 µg/ml kanamycin was diluted 100-folds, cultured at 37 
o
C  until the OD600 
reached ~ 0.6, and then cooled down to 20 
o
C. Expression was induced by the addition of 
0.5mM isopropyl β-D-1-thiogalactopyranoside (IPTG), after shaking for 6 hrs cells at 20 
o
C, the cells were harvested by centrifugation at 6,000g for 10 min. at 4 
o
C and finally 
stored at -80 
o
C before purification. Cells were thawed and all the purification steps were 
performed at 4 
o
C. Cells were resuspended in binding buffer (20 mM Tris, 500 mM NaCl, 
5 mM imidazole, 10 mM β-Me, pH = 7.5) supplemented with 1 mM 
phenylmethanesulfonylfluoride (PMSF), 4 µg/mL leupeptin and 2 µg/mL pepstatin, 
sonicated using a Heat systems W-380 ultrasonic processor, and centrifuged at 16,000g 
for 20 min. to remove cell debris. The supernatant from the cell lysate was applied to Ni-
NTA resin (1.5 cm x 5 cm) which had been equilibrated with binding buffer at rate of 1 
mL/min and non-bound proteins eluted from the column by first washing with 5 column 
volume of binding buffer followed by 20 column volume of wash buffer (20 mM Tris, 
500 mM NaCl, 60 mM imidazole, 10 mM β-Me, pH = 7.5). DXS (wildtype and the 
desired mutants) was eluted using elution buffer (20 mM Tris, 500 mM NaCl, 250 mM 
imidazole, 10 mM β-Me, pH = 7.5). Fractions containing protein were dialyzed at 4 oC 
overnight against 2L of 20 mM Tris, 100 mM NaCl, 10 mM β-Me, pH = 7.5 and 
concentrated using an Amicon ultra centrifugation filter. Final yield from the expression 
was 7-8 mg/L of culture. Enzyme was flash frozen in liquid nitrogen, stored at -80 
o
C and 
the purity of the DXS (wildtype or the mutant proteins) were evaluated by SDS-PAGE.  
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2.2.6 Overexpression and purification of DXR 
 
DXR was expressed in E. coli BL-21 B(DE3) cells. An overnight culture of E. 
coli in LB broth containing 100 µg/ml ampicillin was diluted 100-fold and cultured at 37 
°C with continuous shaking. The temperature of the culture was lowered to 30 °C when 
the OD600 reached ~ 0.6 and DXR expression was induced by the addition of 1 mM 
IPTG. Cells were cultured for another 5 hours at 30°C, harvested by centrifugation at 
6,000g, and stored at -80 °C. The protocol mentioned above for DXS purification was 
used to purify recombinant DXR.  The final yield from the expression was 9-10 mg/L of 
culture. 
 
2.2.7 Determination of D-GLP and 1-Deoxy-D-xylulose-5-phosphate (DXP) 
concentration 
 
D,L-GLP was obtained from Sigma Aldrich as a suspension in water. 
Concentration of D-GLP was measured spectrophotometrically using glyceraldehyde-3-
phosphate dehydrogenase (GAPDH).  A reaction mixture (0.5 mL) containing 30 mM 
sodium pyrophosphate buffer (pH = 8.6), 5 mM L-cysteine, 0.6 mM NAD
+
, 0.6 mM 
sodium arsenate, and D,L-GLP at concentration less than 0.2 mM were incubated at 30 
°C for 10 min, the reaction initiated with 2 µg of GAPDH (Novus Biotechnology), and 
the progress of the reaction monitored spectrophotometrically at 340 nm.   The final 
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concentration of D-GLP was calculated based on the production of NADPH (ε340 = 
6,220M
-1 
cm
-1
).   
 
DXP was purchased from Sigma Aldrich as the sodium salt. The salt was 
resuspended in 10 mM HEPES buffer (pH = 6.0), and the concentration was measured 
spectrophotometerically using DXR. A reaction mixture (0.5 mL) containing of 100 mM 
HEPES (pH = 8.0), 1 mg/mL BSA, 1.5 mM MnCl2, 0.3 mM NADPH, and DXP at 
concentration less than 0.1 mM were incubated at 37
o
C for 5 min, the reaction initiated 
with 1.25 g of DXR, and the progress of the reaction monitored spectrophotometrically 
at 340 nm. Final concentration of DXP was calculated based on the consumption of 
NADPH (ε340 = 6,220M
-1 
cm
-1
). 
 
2.2.8  DXS-DXR coupled assay  
 
The DXS-DXR coupled assay solution consists of 100 mM HEPES buffer (pH = 
8.0), 100 mM NaCl, 1 mg/ml BSA, 1 mM thiamine pyrophosphate (TPP), 1.5 mM 
MnCl2, 2 mM β-Me, 0.15 mM NADPH, 0.2 mg/ml DXR, and varying concentrations of 
pyruvate or D-GLP.  Steady-state kinetics studies were performed by varying pyruvate or 
D-GLP at fixed saturating concentration of the co-substrate.  A DXS-DXR reaction 
solution was incubated at 37 °C for 5 min, the reaction was initiated by addition of 358 
nM DXS, and the progress of the reaction monitored spectrophotometrically at 340 nm 
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for the consumption of NADPH.  NADPH consumption directly corresponds to the 
production of DXP. Assays were performed in triplicate and the data were fitted using 
equation 1 as discussed in section 2.11 to calculate the steady-state kinetic parameters. 
 
2.2.9 Product inhibition of DXS by DXP  
 
Product inhibition is studied using a modification of the HPLC assay (Brammer 
and Meyers 2009). This assay involves the modification of the unreacted substrate and 
product with 2,4-dinitrophenylhydrazine (2,4-DNP) followed by separation and 
quantification of the resulting 2,4-DNP adducts.  A 0.25 mL reaction mixture consisting 
of 100 mM HEPES buffer (pH = 8.0), 80 mM NaCl, 1 mg/ml BSA, 5 mM MgCl2, 1 mM 
thiamine pyrophosphate, 2 mM β-Me, and variable concentrations of of pyruvate, D-
GLP, and DXP was incubated at 37 °C for 5 min. The reaction was initiated by addition 
of 573 nM DXS and, at the desired time, an aliquot (50 µL) was removed and quenched 
into equal volume of cold methanol, and incubated at 4°C for 20 min. Samples were 
centrifuged and a 50 µL aliquot of the supernatant was incubated with equal volume of 
2,4-DNP reagent (100 mM 2,4-DNP in 2N H2SO4). After a 5min. incubation, the pH was 
adjusted to 5-7 by addition of 36 µL 4M Tris buffer (pH = 10.0), and then centrifuged to 
remove excess 2,4-DNP. Samples were stored at -20
o
C before HPLC analysis. The DNP 
derivatives of pyruvate, D-GLP, and DXP were separated using a 5 µm Discovery
®
 C18 
column (25 cm × 4.6 mm) developed using the following conditions:  flow rate = 1.5 
mL/min; solvent A, 100 mM ammonium acetate, 0.05% TFA (pH = 4.6); solvent B, 
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acetonitrile, 0.05% TFA; 20% - 35% solvent B over 12 min and then 35 – 60% solvent B 
over 2 min.  When varying [pyruvate] at one fixed [D-GLP], the concentrations used for 
the initial velocity kinetic experiments were as follows:  D-GLP, 1.0 mM; pyruvate, 0.26, 
0.50, 0.75, or 4.0 mM); and DXP, 0, 0.2, 0.3, or 0.4 mM.  The DXP hydrazone peak area 
was measured and the DXP concentration was determined against a standard curve 
generated using DXP hydrazone.  When varying [D-GLP] at one fixed [pyruvate], the 
concentrations used for the initial velocity kinetic experiments were as follows:  
pyruvate, 0.3 mM; D-GLP, 0.05, 0.1, 0.25, and 0.50 mM; and DXP, 0, 0.2, 0.3, or 0.4 
mM.  The D-GLP hydrazone peak area was measured and the D-GLP concentration was 
determined compared against a standard curve generated using D-GLP hydrazone.. 
Assays were performed in duplicate and the data was fitted and analyzed using equations 
discussed in section 2.11. 
 
2.2.10 Inhibition of DXS by Fluoropyruvate (F-Pyr) 
 
Initial reaction velocities were determined using the DXS-DXR coupled assay as detailed 
in Section 2.8.  When varying [pyruvate] at one fixed [D-GLP], the concentrations used 
for the initial velocity kinetic experiments were as follows:  D-GLP, 0.5 mM; pyruvate, 
0.1, 0.18, 0.5, or 2 mM; and F-Pyr, 0, 25, 50, 75, or 100 µM.  When varying [D-GLP] at 
one fixed [pyruvate], the concentrations used for the initial velocity kinetic experiments 
were as follows:  pyruvate, 2 mM; D-GLP, 0.025, 0.05, 0.125, or 0.25 mM; and F-Pyr, 0, 
25, 50, 75, or 100 µM. Assays were performed using 115nM of D. radiodurans DXS in 
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triplicate and the data were fitted using nonlinear least-squares regression analysis using 
equation discussed in section 2.11. 
 
2.2.11 Analyzing the initial velocity kinectic data 
The steady state initial velocity for DXS measured at various concentrations of 
pyruvate and D-GLP were fit to eq 2 using nonlinear regression analysis in Sigma-Plot 
12.0   
Equation 1 
 
Equation 2 
 
Equation 3    
 
Equation 4 
  
Equation 5  
 
Equation 6  
ν = 𝑽𝒎𝒂𝒙 [𝑷𝒚𝒓][𝑮𝑳𝑷]
𝑲𝒊𝑷𝒚𝒓𝑲𝒎𝑮𝑳𝑷+𝑲𝒎𝑮𝑳𝑷 𝑷𝒚𝒓 +𝑲𝒎𝑷𝒚𝒓  𝑮𝑳𝑷 +  𝑷𝒚𝒓 [𝑮𝑳𝑷]
 
ν = 𝑽𝒎𝒂𝒙 [𝑷𝒚𝒓][𝑮𝑳𝑷]
𝑲𝒊𝑷𝒚𝒓𝑲𝒎𝑮𝑳𝑷+𝑲𝒎𝑮𝑳𝑷 𝑷𝒚𝒓 +  𝑷𝒚𝒓 [𝑮𝑳𝑷]
 
ν = 𝑽𝒎𝒂𝒙 [𝑷𝒚𝒓]
𝑲𝒎𝑷𝒚𝒓 (𝟏+
 𝑰 
𝑲𝒊
)+  𝑷𝒚𝒓 
 
 
 
ν=
𝑽𝒎𝒂𝒙 [𝑷𝒚𝒓][𝑮𝑳𝑷]
𝑲𝒎𝑮𝑳𝑷 𝟏+
[𝑰]
𝑲𝒊
  + [𝑮𝑳𝑷]  𝟏+
[𝑰]
𝑲𝒊
 
 
ν  =
𝑽𝒎𝒂𝒙 [𝐒]
𝑲𝒎 +[𝑺]
 
Slope = (K
mGLP
/ V
max
) (1 + K
iPyr 
/ [Pyr]) 
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Data for inhibition of fluoropyruvate against pyruvate and D-GLP were fit to equation 4 
and 5 respectively at fixed concentration of the second substrate, where [I] is the 
concentration of fluoropyruvate and Ki is the inhibition constant with respect to 
fluoropyruvate. Data for product inhibition (DXP) was fit to equation 4 and 5 for 
pyruvate and D-GLP respectively, and in this case [I] represents the concentration of 
DXP and Ki is the inhibition constant associated with it. 
 
2.3 Results and Discussion 
 
2.3.1 Overexpression, purification of DXS and coupled assay 
 
The wild type D. radiodurans dxs gene (DXS-WT) with a N-terminal His6 tag 
was codon optimized (codon adaptive index value = 0.98), synthesized by GeneArt and 
cloned in pET28a(+) vector using NdeI and XhoI restriction sites. A series of DXS 
mutants were designed near the active site pocket (Xiang et al. 2007) using DXS-WT as 
template by the Quikchange site-directed mutagenesis method or the overlap extension 
method (Ho et al. 1989). DXS-WT and the mutant enzymes (all possessing N-terminal 
His6 tag) were affinity purified using the Ni-NTA resin and the expression yield varied 
from 6-8 mg per liter of culture, with >95% purity (Figure 2.4 and supplementary figure 
S3).  
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 There is no convenient, HTS-compatible assay to 
directly measure DXS activity.  Therefore, E. coli DXR was 
cloned, over-expressed, and purified to establish a 
straightforward coupled assay to measure DXS activity.  The 
DXS reaction is coupled to the DXR catalyzed NADPH-
dependent reduction of DXP to MEP, which is monitored by 
the decrease in A340. 
 
 
2.3.2 Determination of the kinetic parameters for DXS-WT and the mutant DXS 
proteins 
 
DXS is a TPP and Mg
2+
/Mn
2+
-dependent enzyme which belongs to the family of 
transketolase (TK) family of enzyme exisiting as dimer (Hawkins, Borges and Perham 
1989). The folding pattern and dimer organization in the active site pocket for TPP 
binding in crystal structre of D. radiodurans and E. coli DXS has been reported to be 
different than that observed for transketolase and pyruvate dehydrogenase (other 
members of the transketolase family) (Xiang et al. 2007). D. radiodurnas DXS has three 
domains: domain I, residue 1-319; domain II, residue 320-495, and domain III, residue 
496-629. The TPP molecule amino-pyrimidine ring interacts with domain II and the 
pyrophosphate moiety interacts with domain I of the same monomer (Figure 2.5). While 
in case of TK and PDH, which also have three domains; the active site is located between 
 
Figure 2.4: SDS-PAGE, 
Lane-1 Marker, Lane-2 
D. rad DXS, and Lane-3 
E. coli DXR 
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domain I of one monomer and domain II of the other monomer. This difference in 
domain organization has been associated to the relatively short linker between domain I 
and II (20 residues) in DXS, as compared to that of TK and PDH (95 residues) and could 
be the reason for different kinetic mechanism behavior as compared to the traditional 
TPP dependent enzymes.   
 
 
 
 
 
 
Figure 2.5: Schematic drawing of the D. rad DXS depicting bound TPP with domain I 
(yellow), II (red), and III (blue) of the same monomer. 
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Figure 2.6: Sequence comparison of DXS from H. influenza, V. colerae, P. vivax (after 
gap removal), P. falciparum (after gap removal), D. radiodurans, B. anthracis and  M. 
tuberculosis using Clustal W2. (gap = sequence of residues in plasmodium, which shares 
no homology with DXS from other species). 
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Figure 2.6: Continued 
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Amino acids in DXS involved in the binding of the cofactor TPP and the substrate 
D-GLP are highly conserved in all the species which uses NMVA pathway for isoprenoid 
biosynthesis. A sequence comparison of Haemophilus influenza, Vibrio colerae, 
Plasmodium vivax, Plasmodium falciparum, Deinococcus radiodurnas, Bacillus 
anthracis and Mycobacterium tuberculosis shows the conserved region for TPP and D-
GLP binding (Figure 2.6). In DXS, C-2 atom of thiazolium ring is exposed to the solvent 
while rest of the molecule is buried inside tighly bound within domain I and II. The 
amino-pyrimidine ring of TPP interacts through carboxylate of Glu 373, π-stacking 
interaction with Phe 398, van der Waals interaction with Ile 371 and Ile 187 (all part of 
domain II).  
 
Major role played by domain I is to support the pyrophosphate moiety of TPP 
through polar interaction with amino acid. The highly conserved His 52 (or His 49 in E. 
coli) in TPP utilizing enzyme has been proposed to play role in distributed proton transfer 
during catalysis. E. coli DXS mutant H49Q has been shown to be deficient in catalyzing 
the conversion of pyruvate and D-GLP to DXP (Querol et al. 2001). In contrast domain II 
plays major role in activating the thiazolium ring in TPP. Glu 373 of this domain is 
involved in the hydrogen bonding with N-1 atom of amino-pyrimidine ring and may help 
in the activation of the C-2 of the thiazolium ring though formation of catalytically potent 
ylide system. Replacement of Glu 373 with alanine leads to the completely inactive 
enzyme (Xiang et al. 2007), this residue is equivalent to Glu 56 oxalyl-CoA 
decarboxylase, another TPP dependent enzyme and mutation of this residue to alanine 
55 
 
also led to complete inactive enzyme (Berthold et al. 2007). Carboxylate group of Glu 
373 is ~ 1.8 Å apart from the hydrogen of N1’ of TPP,  
 
 
 
 
 
 
 
 
 
       
 
 
 
 
 
Figure 2.7: The Proposed Reaction Mechanism of DXS 
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abstraction of this hydrogen by Glu 373 leads to the formation of the 1’, 4’-
iminopyrimidine tautomer of TPP to facilitate the deprotonation of C-2 of thiazolium 
ring. After generation of this ylide, the C-2 carbon attacks the carboxylic group of 
pyruvate through nuclephilic addition reaction, which later undergoes decarboxylation to 
generate an activated C-2 pyruvate. This activated C-2 of pyruvate further attacks the 
aldehyde group of D-GLP through nucleophilic addition and later undergoes 
rearrangement to yield DXP and activated ylide (Figure 2.7). 
 
Replacement of Asn 183 by alanine leads to an inactive enzyme, because of the 
role played by Asn 183 in the coordination of Mg
2+
/Mn
2+
. Mutation of Asn 181 to Ala is 
an active mutant with the same Km as wildtype, but with a 50% decrease in kcat/KM 
(Table 2.2 and 2.3).  This data suggest that Asn 181 has role in binding TPP in an 
optimum configuration for catalysis. On the other hand D-GLP binding was studied by 
mutating the residue which are involved in direct interaction with the substrate: His 304, 
Tyr 395, Arg 423, and Asp 430 (Figure 2.8). In previous report the conversion of Arg 401 
and Arg 480 to alanine each lead to completely inactive R401A and R480A DXS 
mutants, suggesting that these two residues are important in catalysis, most likely by 
binding to the phosphate moiety of D-GLP (Xiang et al. 2007).  
 
For Tyr 395 the role of hydroxyl group as well as the importance of aromatic ring 
has been studied here. Hydroxyl group interacts directly with D-GLP, as the mutant 
Y395A leads to 10-fold increase in the value of Km and 25-fold decrease in the value of 
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kcat/Km value. This mutant was rescued to a certain extent by Y395F mutant which 
showed 15-fold lower kcat/Km value (Table 2.2), indicating the importance of both 
hydroxyl group and aromatic system.  
Table 2.2: Steady-state Kinetic Parameters for DXS WT and DXS Mutants for D-GLP 
 
 
 
 
 
 
 
 
 
 
 
 
 (*Apparent kinetic constants were measured by varying the initial concentration of 
DGLP at 2.0 mM pyruvate). 
 
 Steady-state Kinetics Parameters for D-GLP* 
 Km (mM) kcat (s
-1
) kcat/Km (s
-1
M
-1
) 
DXS WT 0.05 ± 0.01 7.9 ± 0.4 1.45 ± 0.08 × 10 
5
 
H82A 0.03 ± 0.01 0.37 ± 0.02 1.28 ± 0.07 × 10 
4
 
Y395F 0.59 ± 0.04 5.9 ± 0.2 1.01 ± 0.03 × 10 
4
 
Y395A 0.67 ± 0.05 3.9 ± 0.1 5.8  ± 0.1 × 10 
3
 
D430A 0.12 ± 0.01 7.7 ± 0.2 6.6  ± 0.2 × 10 
4
 
H434A 0.23 ± 0.01 9.6 ± 0.3 4.2 ± 0.1 × 10 
4
 
R423A 12.3  ± 3.2 1.7 ± 0.3 1.4  ± 0.2 × 10 
2
 
R423K 0.6 ± 0.1 6.4 ± 0.2 1.1  ± 0.1 × 10 
4
 
H304A 0.08 ± 0.02 0.9 ± 0.1 1.1  ± 0.1 × 10 
4
 
N181A 0.03 ± 0.01 0.43 ± 0.02 3.3  ± 0.1 × 10 
3
 
N183A 0 0 0 
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The other amino acids studied here were Asp 430, H434 and Arg 423. The 
mutants D430A and H434A have exhibit relatively small changes in the kinetic 
parameters, while R423A mutant showed a significant increase in Km value (250-folds) 
from 0.05 mM to 12.3 mM and decrease in the value of kcat/Km value (1000-folds) 
relative to the DXS WT, suggesting that Arg 423 recognizes the phosphate moiety of D-
GLP. Note that the Km value for DGLP for the R423A mutant is approximately 
equivalent to the Km for glyceraldehyde in DXS WT (14mM) (Hahn et al. 2001), 
providing additional evidence that the guanidino moiety of R423 interacts with the 
phosphate of D-GLP. D-GLP is a substrate for the R423K mutant with a 10-fold 
increases in the value of Km and 13-fold decrease in the value of kcat/Km. The kcat/Km 
value for the R423K mutant is approximately 100-fold higher than the kcat/Km  value for 
the R423A mutant, again consistent with the importance of positive charge of the 
guanidine group in stabilizing the negative charge of D-GLP phosphate.  
 
The previous section detailed how the DXS mutants affected the kinetic 
parameters measured when D-GLP was the variable substrate.  The focus of this section 
is the effect of DXS mutation on the kinetic parameters measured when pyruvate is the 
variable substrate.  The H434A mutants showed a significant increase in the value of Km 
(6-fold) and no significant changes in the kcat/Km values for obsereved (Table 2.3, 2.4). 
H82A mutant showed only 5% turnover as compared to DXS WT and no change in the 
value of Km for pyruvate and DGLP, indicating the importance of this histidine as proton 
acceptor/donor. While H304A mutant showed change in Km (6-fold higher), kcat/Km (45-
fold lower), and only 11% turnover indicating the possibility of histidine as proton 
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acceptor/donor and binding of pyruvate through ionic interactions. Mutant DXS Y395A, 
Y395F, R423K, and D430A showed no significant difference in the kcat/Km value for 
pyruvate, because of their role in supporting D-GLP binding as discussed previously. 
Steady-state parameters for R423A were not determined because the saturating 
concentration of D-GLP (~10 Km) required was very high (Km = 12.3 mM). 
Figure 2.8: Stereo view of the DXS active site depicting active C-2 of the thiazolium 
ring, residues from domain I (H82, D154, N181, N183, and H304) and domain II (E373, 
Y395, R401, R423, D430, H434, and R480). 
 
 
 
 
60 
 
Table 2.3: Steady-state Kinetic Parameters for DXS WT and DXS Mutants for pyruvate 
 
 
 
          
 
 
 
 
 
 
 
 
 (**Apparent kinetic constants were measured by varying the initial concentration of 
pyruvate at 0.5 mM D-GLP, 
a
Not determined). 
 
 
 
 
 Steady-state Kinetics Parameters for Pyruvate** 
 Km (mM) Kcat (s
-1
) Kcat/Km (s
-1
M
-1
) 
DXS WT 0.28 ± 0.03 7.4 ± 0.3 2.64 ± 0.01 × 10 
4
 
H82A 0.23 ± 0.02 0.38 ± 0.01 1.7 ± 0.1 × 10 
3
 
Y395A 0.16 ± 0.01 3.6 ± 0.1 2.18 ± 0.03 × 10 
4
 
Y395F 0.19 ± 0.01 2.94 ± 0.02 1.57 ± 0.01 × 10 
4
 
D430A 0.52 ± 0.03 7.2 ± 0.2 1.4 ± 0.3 × 10 
4
 
H434A 1.7 ± 0.1 9.9 ± 0.2 5.9 ± 0.1 × 10 
3
 
R423A -----
a
 -----
 a
 -----
 a
 
R423K 0.06 ± 0.01 3.9  ± 0.1 6.5  ± 0.2 × 10 
4
 
H304A 1.7 ± 0.5 0.9 ± 0.1 5.8 ± 0.8 × 10 
2
 
N181A 0.17 ± 0.02 3.3 ± 0.1 1.9 ± 0.01 x 10 
4
 
N183A 0 0 0 
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Table 2.4: Comparison of the Activity of the Mutant DXS Protein relative to the DXS 
WT. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 (*Apparent kinetic constants were measured by varying the initial concentration of 
DGLP at 4.0 mM pyruvate, **Apparent kinetic constants were measured by varying the 
intial concentration of pyruvate at 0.5 mM D-GLP, 
a
Not determined). 
 
 
 
Enzyme Relative Vmax value (%) 
with D-GLP as varying 
substrate* 
Relative Vmax value (%) 
with Pyr as varying 
substrate** 
DXS WT 100 ± 4 100 ± 4 
E373A 0 0 
H82A 4.8 ± 0.2 5.1 ± 0.2 
Y395A 50.7 ± 0.9 39.8 ± 0.3 
Y395F 77.6 ± 2.3 48.3 ± 0.7 
D430A 99.8 ± 2.4 97.5 ± 1.9 
H434A 125.2 ± 3.7 133 ± 3 
R423A 22.3 ± 3.9 ----
a 
R423K 80.4 ± 2.4 53.6 ± 1.6 
H304A 11.2 ± 0.7 13.1 ± 1.7
 
N181A 42.7 ± 0.9 44.8 ± 1.6 
N183A 0 0 
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2.3.3 Pyruvate and D-GLP binding study 
 
Family of enzymes which uses the TPP cofactor has been well studied. Steady-
state kinetics, dead-end inhibition, product inhibition and crystallization studies have 
been used to elucidate the mechanism of substrate binding and reaction catalysis (Frank, 
Leeper and Luisi 2007). All TPP-dependent enzymes catalyzes two successive half 
reactions, the first step involves the attack of activated TPP (ylide system at C-2) to first 
substrate. The next step could occur in three possible ways, the most common being the 
classical ping-pong mechanism where the first product is released generating a 
metastable enzyme-intermediate complex.  Product formation follows after onto the 
second substrate. Another possible second half reaction proceeds through an ordered 
mechanism, in which the first product can only be released if the second substrate is 
bound to the active site. For an ordered mechanism like this, the first substrate binds 
tightly and irreversibly, while the second substrate could only bind in the presence of first 
substrate. The last possible second half reaction could proceeds through random 
sequential mechanism, where binding of both the substrates are reversible and 
independent of each other (Figure 2.3)  
 
Most of the known TPP-dependent enzymes like phosphoketolase-2 and pyruvate 
dehydrogenase (Yevenes and Frey 2008, Liu et al. 2001) follow a ping-pong mechanism. 
For phosphoketolase-2, first step involves the binding of either fructose-6-phosphate or 
xylulose-5-phosphate followed by release of either erythrose-4-phosphate or D-GLP, 
respectively, while proton acts as an acceptor in the second step resulting in the release of 
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acetyl phosphate. The kinetic mechanism of the substrate binding has been studied 
previously for DXS from Escherichia coli, Rhodobacter encapsulates and Haemophilus 
influenzae (Eubanks and Poulter 2003, Brammer et al. 2011, Matsue et al. 2010).  Work 
from the Poulter lab demonstrates that the R. capsulatus DXS has an ordered sequential 
mechanism (Eubanks and Poulter 2003), using dead-end inhibition by fluoropyruvate and 
14
CO2 trapping experiments. These researchers found that the conversion of pyruvate to 
14
CO2 is inefficient in absence of D-GLP, eliminating the ping-pong mechanism a 
classical pathway used by many TPP-dependent enzymes. Studies on E. coli using 
methyl-acetylphosphonate (MAP) as a dead-end inhibitor and tryptophan fluorescence 
quenching experiment demonstrate the kinetic mechanism for this enzyme is random 
sequential (Brammer et al. 2011). The binding of pyruvate and D-GLP to E. coli DXS 
was found to be reversible and completely independent of each other.  This is in contrast 
to the ordered sequential mechanism of R. capsulatus DXS, which requires that D-GLP 
can only bind to the enzyme in presence of pyruvate. 
 
In this study of D. radiodurans DXS, a double reciprocal analysis of the 
substrates were used. Along with these studies, we also carried out product inhibition 
using DXP and dead-end inhibition using fluoropyruvate (F-pyr) to aid in defining the 
kinetic mechanism. Double reciprocal analysis at lower concentrations of D-GLP (0.01-
0.03mM) and pyruvate (0.02mM-0.06mM) at different, but fixed concentrations of the 
other substrate revealed a non-competitive pattern with change in both slope and intercept 
(Figure 2.9, 2.10), strongly suggesting a random sequential mechanism. These results 
demonstrate that both substrates bind to DXS independent of each other.  For an ordered 
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mechanism, we would have observed a competitive pattern for D-GLP and an 
uncompetitive pattern for pyruvate in case of ping-pong mechanism. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9: Double reciprocal analysis of initial velocities of pyruvate at different fixed 
concentration of D-GLP. Kinetic analysis was performed at sub-saturating concentration 
of D-GLP: 0.01 mM (●), 0.014 mM (o), 0.02 mM (▼), and 0.03 mM (Δ). 
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Figure 2.10: Double reciprocal analysis of initial velocities of D-GLP at different fixed 
concentration of pyruvate. Kinetic analysis was performed at sub-saturating concentration 
of pyruvate: 0.02 mM (●), 0.03 mM (o), 0.04 mM (▼), and 0.06 mM (Δ). 
 
Product inhibition studies were next used to determine the mechanism of substrate 
binding and product release in the D. radiodurans DXS catalyzed reaction. DXP was 
used as product inhibitor against pyruvate and D-GLP.  We found that DXP is a weak 
inhibitor with ~60% inhibition at concentration of 0.4 mM, yielding a Ki in low 
millimolar range (Table 2.5). Product inhibition by DXP, as we report here, provides a 
possible explanation of change in double reciprocal plots at higher concentration of 
pyruvate and D-GLP for R. capsulatus and E. coli DXS as compared to the plot at lower 
concentration (Brammer et al. 2011, Matsue et al. 2010). DXP showed a competitive 
pattern vs. pyruvate indicating that DXP competes for the same enzyme form as pyruvate 
(Figure 2.11), despite the chemical resemblance between DXP and D-GLP. When D-GLP 
was the varied substrate at fixed sub-saturating concentration of pyruvate DXP yielded a 
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non-competitive inhibition pattern (Figure 2.12). This shows that that DXP and D-GLP 
do not bind to the same enzyme form. At a saturating concentration of pyruvate, no 
inhibition was detected by DXP when D-GLP was varied substrate.  On the other hand, 
DXP inhibition was still observed at saturating concentration of D-GLP when pyruvate 
was the variable substrate. 
 
 
 
 
 
 
 
 
 
 
Figure 2.11: Double reciprocal analysis of initial velocities of DXS inhibition by DXP at 
different initial concentration of D-GLP. Kinetic analysis were performed at following 
concentration of DXP: 0 mM (●), 0.2 mM (o), 0.3 mM (▼), and 0.4 mM (∇), and the 
initial concentration of D-GLP was fixed at 1 mM. 
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Figure 2.12: Double reciprocal analysis of initial velocities of DXS-inhibition by DXP at 
different fixed concentration of pyruvate. Kinetic analysis were performed at following 
concentration of DXP: 0 mM (●), 0.2 mM (o), 0.3 mM (▼), and 0.4 mM (∇), and the 
initial concentration of D-GLP was fixed at 0.3 mM. 
 
Table 2.5: Observed inhibition pattern and inhibition constant for DXS with DXP and 
fluoropyruvate. 
 
 
 
 
 
 
 
Inhibitor Substrate Pattern Ki (µM) 
DXP Pyr Competitive 128.7 ± 32.1 
DXP D-GLP Non-competitive 828.3 ± 155.5 
F-Pyr Pyr Competitive     3.3 ± 0.4 
F-Pyr D-GLP Non-competitive   57.1 ± 3.2 
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F-Pyr was also used as a dead-end inhibitor to study the mechanism of binding in D. 
radiodurans DXS.  F-Pyr is competitive vs. pyruvate and non-competitive vs. D-GLP 
(Figure 2.13 and 2.14) and exhibits a Ki = 3.3 ± 0.4 M when pyryvate was the variable 
substrate. . For an ordered or random sequential mechanism, F-pyr vs. D-GLP would 
yield a non-competitive pattern, while ping-pong mechanism would yield an  
 
 
 
 
 
 
 
Figure 2.13: Double reciprocal analysis of initial velocities of DXS inhibition by F-Pyr at 
different fixed concentration of pyruvate. Kinetic analysis were performed at following 
concentration of F-Pyr: 0 µM (●), 25 µM (o), 50 µM (▼), 75 µM (∇), and 100 µM (■), 
and the initial concentration of D-GLP was fixed at 0.5 mM. 
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Figure 2.14: Double reciprocal analysis of initial velocities of DXS inhibition by F-Pyr at 
different fixed concentration of D-GLP. Kinetic analysis were performed at following 
concentration of F-Pyr: 0 µM (●), 25 µM (o), 50 µM (▼), 75 µM (∇), and 100 µM (■), 
and the initial concentration of pyruvate was fixed at 2 mM. 
 
uncompetitive pattern.  A result from inhibition study by F-Pyr with respect to D-GLP 
was difficult to distinguish between non-competitive and uncompetitive.  However, the 
inhibition pattern by DXP and the double reciprocal studies of varying both substrates, 
the best fit to data is a random sequential mechanism of D. radiodurans DXS. This 
random sequential mechanism can degenerate to ordered sequential mechanism when the 
rate of reaction is more through path A than path B (Figure 2.15).  
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Figure 2.15: Random sequential pathway proposed for the reaction catalyzed by DXS.  
 
2.4 Summary 
 
Non-mevalonate pathway represents a unique opportunity for the development of  
novel inhibitors to treat drug resistant pathogens, both bacteria and parasites.  The 
enzymes involved in NMVA pathway  have no resemblance or homology homology to 
the enzymes of the mevalonate-dependent pathway found in man and other mammals. 
The reaction catalyzed by DXS is the rate determining step (Estévez et al. 2001) of 
isoprenoid synthesis in A. thaliana as well as the source of DXP for the synthesis of 
vitamins B1 and B6 in Plasmodium sp. (Müller et al. 2010). In order to develop a novel 
inhibitor/lead against DXS, the reaction mechanism of DXS was studied using site-
directed mutagenesis, double reciprocal studies, product inhibition and dead-end 
inhibitor. 
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Chapter 3: Overexpression of P. vivax DXS in E. coli  
 
3.1 Introduction 
 
3.1.1 Malaria life cycle 
 
Recent report by World Health Organization (WHO) have pointed out the 
increasing number of reported cases of various infectious diseases (WHO 2010), 
specially the most dreadful diseases known to human kind such as malaria (~81 millions) 
and tuberculosis (~5.8 millions) globally. Malaria is one of the most appalling forms of 
disease with shocking increase in number of incident in twenty first century (Petersen, 
Eastman and Lanzer 2011a, Carlton, Sina and Adams 2011). These higher number of 
cases of malaria has been associated with increasing drug resistance in plasmodium 
species in African, South Asian and South American continent (Ruetz et al. 1996).  
 
There has been 156 named species of plasmodium genus which infects 
vertebrates, with P. falciparum, P. vivax, P. ovale, P. knowlesi and P. malariae being the 
five major species responsible for malaria in humans 
(http://www.cdc.gov/malaria/about/disease.html ). The malaria parasite lives a complex 
life cycle in two hosts (Anopheles mosquito and vertebrates). In first stage, a parasite 
infected female Anopheles mosquito transmit the sporozites (infectious form of 
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plasmodium) while feeding on human host (Figure 3.1). These sporozites infects the liver 
cells and asexually reproduces to multinuclear schizonts and later rupture to releases 
merozoites. These merozoites infect the red blood cells (RBC), where they again 
reproduce asexually into multinuclear schizonts by feeding on the cytoplasm and 
hemoglobin. Upon maturation of the schizonts, the RBC ruptures with the release of 
merozoits which then invades more RBC. A small percentage of the merozoites that  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Life cycle of Malaria parasite in Anopheles mosquito and humans (Adopted 
from Center for Disease Control and Prevention). 
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invades the erythrocytes do not develop into schizonts, but instead differentiate into 
micro and macrogametocytes (male and female cells, respectively). These gametocytes 
have no activity within the human host and must be ingested into a female Anopheles 
mosquito for sexual reproduction. Once in the stomach of the mosquito, the micro- and 
macrogametocytes fuse to form an oocyst, which fills with the infectious sporozoites. 
 
These sporozoites migrate to the salivary gland in the female Anopheles after 
oocyst rupture, ready to infect the next victim bitten by the mosquito. The lifecycle of 
Plasmodium, ultimately involving both mosquito and mammalian hosts, coupled to the 
complex interplay of the hepatic and erythrocyte stages of the protozoan infection present 
quite a challenge to the development of new antimalarial drugs. In case of P. vivax and P. 
ovale a dormant stage of hynozites can form, which can replaces by invading the 
bloodstream in weeks or even year later.  
 
3.1.2 Compartmentalization of metabolic pathways in plasmodium species 
 
The whole genome sequence of P. falciparum and P. vivax has been published 
recently and gave vital information about the metabolic pathway plasmodium species 
used for survival and resistance (Carlton et al. 2008, Gardner et al. 2002). Infection by P. 
falciparum has been mostly dominant in African continent, while P. vivax is widespread 
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in Asian and American continent because P. vivax cannot infect duffy blood group 
negative reticulocytes (Mendis et al. 2001), a trait found in people from Africa. Both the 
plasmodium species share some common genomic features such as the total number of 
genes (~ 5400), while differ in other features such as GC % content (19.4 % in 
falciparum and 42.3 % in vivax). Using bioinformatics tools and sequencing results, some 
of the important biological pathways such as complete type II fatty acid synthesis, 
isopentenyl pyrophosphate (IPP) synthesis, iron sulfur cluster assembly, and a 
fragmented haem synthesis have been identified and localized in this parasite. 
 
 All the plasmodium species and other member of the phylum apicomplexa harbor 
apicoplast, an organelle which is homologous to the chloroplast of plants and algae 
(Köhler et al. 1997, McFadden et al. 1996). This organelle consists of 35-kb genome 
which encodes 30 proteins mainly consisting of complete set of tRNAs, ribosomal 
proteins and several unidentified open reading frame (Sato 2011, McFadden 2011). 
Homologs to plant plastid most of the apicoplast targeted proteins are encoded by nuclear 
gene and transported to the organelle through a two steps process. It has been estimated 
that approximately 800 nuclear encoded protein may be targeted to apicoplast (Waller et 
al. 2000). Protein targeted to apicoplast consists of bipartite N-terminal pre-sequence 
consisting of two functional domains: (a) signal peptide and (b) transit peptide (Figure 
3.2). Using acyl carrier protein (ACP) as an example, the role of signal and transit peptide 
has been studied previously (Waller et al. 2000, Zuegge et al. 2001). When transit peptide 
from ACP was fused to N-terminal of green fluorescence protein (GFP), it leads to the 
accumulation of GFP in cytoplasm indicating the importance of signal peptide. On 
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contrary, when just the signal peptide was fused to the N-terminal of GFP all the GFP 
protein was accumulated within the parasitophorous vacuole, not in apicoplast.  
 
 
 
 
 
Figure 3.2: Schematic diagram of apicoplast targeting protein in plasmodium species 
 
This ordered two steps process shows that the signal peptide is important for 
protein to enter within the secretory pathway, then transit peptide play role in directing 
into the apicoplast, and finally transit peptide cleaves off to leave mature protein in 
apicoplast. Over the past years various software’s have been developed to differentiate 
between protein targeted to apicoplast, mitochondria and cytoplasm using the analogy to 
the plastid targeting protein used by plants. Software’s such as SignalP, PSORT, PATS 
and PlasmoAP has been to developed to identify the signal peptide (Petersen et al. 2011b, 
Nakai and Kanehisa 1992, Zuegge et al. 2001). But, so far there is no clear consensus 
regarding the size and cleavage of transit peptide from mature protein. There are two 
ways to characterize the transit peptide presence: (a) net charge at the N-terminal (basic 
versus acidic), (b) presence of enriched aspargine and lysine residue (Foth et al. 2003, 
Ponpuak et al. 2007). Based on the mature apicoplast protein analyzed from P. 
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falciparum it has been shown that transit peptide can varies anywhere between 50 to over 
few hundreds amino acid (Table 3.1). 
Table 3.1: Example of apicoplast targeting proteins 
Apicoplast targeting sequence 
in P. falciparum 
Size of the transit peptide 
 
Comment/ 
References 
1-deoxy-D-xylulose-5-phosphate 
reductoisomerase (DXR) 
49 (Jomaa et al. 1999) 
rRNA methylase 54 Putative 
queuine tRNA-ribosyltransferase 302 Putative 
Alanine-tRNA ligase 367 Putative 
Acyl carrier protein 78 (Waller et al. 2000) 
 
Apicoplast consists of four outer membranes and the mechanism of translocation 
across these membranes is poorly understood. Cleavage of signal peptide and transit 
peptide while passing through these membrane is not understood either (Tonkin, Kalanon 
and McFadden 2008). In plants, stromal processing peptidase (SPP) has been 
characterized for the cleavage of transit peptide, and recently a putative non-plant stromal 
processing peptidase from P.falciparum has been proposed to do the similar chemistry as 
plant SPP (Richter and Lamppa 1999, van Dooren et al. 2002). The cleavage site for 
transit peptide can be found out by serial deletion of gene from N-terminal of the mature 
protein based on Clustal W2 alignment of apicoplast protein with same protein from 
other species, as previously reported for P. falciparum DXR (Jomaa et al. 1999).  
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3.1.3 Targeting non-mevalonate pathway in Plasmodium species 
 
Recent discovery of the Non-mevalonate pathway (NMVA) in eubacteria and 
parasites has opened a new platform for the development of antibiotics and antimalarial 
drugs (Goodman, Su and McFadden 2007, Mbaya et al. 1990, Sacchettini and Poulter 
1997). Based on bioinformatics tool and in vitro studies it has been established that 
NMVA exists in all the plasmodium species and tuberculosis strains, thus making the 
enzymes involved in NMVA as an alluring target for drug discovery. In this study 1-
deoxy-D-xylulose-5-phosphate synthase (DXS), the first enzyme of NMVA pathway in 
P. vivax has been explored. DXS has been cloned and overexpressed in E. coli using 
genomic DNA and codon optimized DNA as a source. Full length DXS with signal and 
transit peptide as well as mature protein without these peptides by serial deletion has also 
been overexpressed. Kinetic parameters have been calculated and compared it to the DXS 
from other species.  
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3.2 Materials and Methods: 
 
3.2.1 Materials 
 
Thiamine pyrophosphate, pyruvate, glyceraldehyde-3-phosphate, 1-deoxy-D-
xylulose-5-phosphate sodium salt, bovine serum albumin and LB-broth were purchased 
from Sigma Aldrich. NADPH was from Alexis Biochemical’s, Ni-NTA resin was from 
Invitrogen, and β-mercaptoethanol (β-Me) was from Fisher. E. coli XL-10 cells, 
deoxynucleotide mix PCR grade, pfuUltra hotstart DNA polymerase and acetonitrile 
(HPLC grade) were purchase from Agilent. The DNA vectors pET28a(+) and 
pET21b(+),  E. coli strains BL-21 B(DE3) and Rosetta B(DE3) cells were purchased 
from EMD Biosciences. DNA sequencing services and primers were purchased from 
MWG operon.  All the other reagents were of the highest quality commercially available.  
 
3.2.2 Cloning of recombinant P. vivax 1-deoxy-D-xylulose-5-phosphate synthase (DXS) 
from P. vivax genomic DNA 
 
P. vivax dxs gene was extracted from strain Sal-1 provided by Dr. John H. Adams 
Lab (Department of Global Health, University of South Florida). PCR primers used were: 
forward primer 5’- CCTAGGATCCGATGATAATGGGAACTTCCTCT -3’ with BamHI 
restriction site (underlined) and 5’- ATCCAAGCTTGTTGGACACCCCTCCTTGCAG-
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3’ as reverse primer with HindIII restriction site (underlined). PCR conditions were 
optimized by varying the concentration of DNA template, primers, concentration of 
DMSO, and annealing temperature. The final optimized reaction conditions used were 50 
ng of the genomic DNA, 10 ng/µL of each primer and 10% DMSO. Thermocycler 
condition used for the amplification of 3333 base pair fragment were 95 
o
C for 4 min., 
followed by 30 cycles of denaturation at 95 
o
C for 30 sec., annealing at 60
o
C for 30 sec, 
elongation at 72 
o
C for 3 minutes 30 seconds and one final elongation step at 72 
o
C for 10 
min. 
 
The PCR product of P. vivax dxs gene with BamHI and HindIII restriction sites 
was used to clone in pET21b(+) with C-terminal His-tag to yield pET21b(+)-vivax-DXS 
plasmid. Briefly, pET21b(+) vector (ampicillin resistance) and PCR product were 
digested with BamHI and HindIII restriction enzyme for 1 hour each at 37 
o
C 
respectively, followed by digestion of pET21b(+) with Antarctic phosphatase for 30 mins 
at 37 
o
C. The digested samples were then run on gel (0.7%) and the appropriate bands 
were extracted for the overnight ligation reaction at 16 
o
C. An aliquot of the ligation 
reaction (4µL) was used to transform E. coli XL-10 cells and plated on LB plate 
supplemented with 100µg/mL ampicillin. Colonies with pET21b(+)-vivax-DXS plasmid 
grew on the plate supplemented with ampicillin. These colonies were cultured and the 
plasmid was extracted for primary screening to confirm the insertion of dxs gene in 
pET21b(+) vector. Cloning was further confirmed by DNA sequencing at MWG operon.  
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3.2.3 Overexpression and purification of P. vivax DXS 
pET21b(+)-vivax-DXS plasmid was used to transform E. coli strain BL-21 and 
Rosetta B(DE3)  E. coli cells. An overnight culture of E. coli in LB broth containing 100 
µg/ml ampicillin and 1% glucose was diluted 100-folds, cultured at 37 
o
C until the  OD600 
reached ~ 0.6 and then cooled down to 20 
o
C. Expression was induced by the addition of 
0.5mM isopropyl β-D-1-thiogalactopyranoside (IPTG), after shaking for 6 more hrs at 20 
o
C, the cells were harvested by centrifuged at 6,000g for 10 min. at 4 
o
C and finally 
stored at -80
o
C before purification. Cells were thawed and all the purification steps were 
performed at 4
o
C. Cells were resuspended in binding buffer (20 mM Tris, 500 mM NaCl, 
5 mM Imidazole, 10 mM β-Me, pH = 7.5) supplemented with 1 mM 
phenylmethanesulfonylfluoride (PMSF), 4 µg/mL leupeptin, 2 µg/mL pepstatin , and 
sonicated using Heat systems W-380 ultrasonic processor, and centrifugation at 16,000g 
for 20 min. to remove cell debris. The supernatant from the Cell lysate was applied on 
Ni-NTA resin (1.5 cm x 5cm) which had been equilibrated with binding buffer at rate of 
1 mL/min and non-bound proteins eluted from the column by first washing with 5 
column volume of binding buffer and 20 column volume of wash buffer (20 mM Tris, 
500 mM NaCl, 60 mM Imidazole, 10 mM β-Me, pH = 7.5). P. vivax DXS was eluted 
using elution buffer (20 mM Tris, 500 mM NaCl, 250 mM Imidazole, 10 mM β-Me, pH 
= 7.5). Fractions containing protein were dialyzed at 4
o
C overnight against 2L of 20 mM 
Tris, 100 mM NaCl, 10 mM β-Me, pH = 7.5 and concentrated using an Amicon ultra 
centrifugation filter. Final yield from the expression was ~40 µg /L of culture from BL-
21 cells and ~80 µg /L of culture from Rosetta B(DE3) cells with ~ 80% purity as judged 
by SDS-PAGE. 
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3.2.4 Cloning of recombinant P. vivax 1-deoxy-D-xylulose-5-phosphate synthase (DXS) 
and constructs without signal and transit peptide from codon optimized P. vivax dxs 
gene 
 
A codon optimized synthetic P. vivax dxs gene with 5’-NdeI and 3’-HindIII 
restriction sites in pUC57 vector was obtained from Genescript, New Jersey. pET21b(+) 
vector (ampicillin resistance) was used to clone in the full length DXS with C-terminal 
His-tag to yield pET21b(+)-DXS (SH-1) plasmid. Briefly, pET21b(+) vector (ampicillin 
resistance) and PCR product were digested with NdeI and HindIII restriction enzyme for 
1 hour each at 37 
o
C respectively, followed by digestion of pET21b(+) with Antarctic 
phosphatase for 30 mins at 37 
o
C. The digested samples were then run on gel (0.7%) and 
the appropriate bands were extracted for the overnight ligation reaction at 16 
o
C. An 
aliquot of the ligation reaction (4µL) was used to transform E. coli XL-10 cells and 
plated on LB plate supplemented with 100µg/mL ampicillin. Colonies with pET21b(+)-
DXS (SH-1) plasmid grew on the plate supplemented with ampicillin. These colonies 
were cultured and the plasmid was extracted for primary screening to confirm the 
insertion of dxs gene in pET21b(+) vector. Cloning was further confirmed by DNA 
sequencing at MWG operon. 
 
 Shorter fragmented construct from SH-2 to SH-9 was constructed by PCR 
extraction of the gene using the set of primer mentioned in Table 3.2 and cloned in 
pET28a(+) vector (kanamycin resistance). The PCR product and the plasmid were 
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digested with NdeI and XhoI restriction enzyme for 1 hour at 37
o
C, followed by digestion 
of pET28a(+) with Antarctic phosphatase for 30 minutes at 37
o
C respectively, followed 
by digestion of pET28a(+) with Antarctic phosphatase for 30 mins at 37 
o
C. The digested 
samples were then run on gel (0.7%) and the appropriate bands were extracted for the 
overnight ligation reaction at 16 
o
C. An aliquot of the ligation reaction (4µL) was used to 
transform E. coli XL-10 cells and plated on LB plate supplemented with 50 µg/mL 
kanamycin. Colonies with respective plasmid grew on the plate supplemented with 
kanamycin. These colonies were cultured and the plasmid was extracted for primary 
screening to confirm the insertion of dxs gene in pET28a(+) vector. Cloning was further 
confirmed by DNA sequencing at MWG operon. 
Table 3.2: Primer used for the DXS constructs (restriction site underlined). 
Construct Type Sequence 
SH-2 Sense 5’  GTAG CAT ATG TAT CCG ACC TCC GCG ACG 3’ 
Antisense 5’ GTAG CTC GAG TTA GTT GCT AAC ACC CTG 3’ 
SH-3 Sense 5’  GTAG CAT ATG GAC AAC CGT GAT CCG CCG 3’ 
Antisense 5’ GTAG CTC GAG TTA GTT GCT AAC ACC CTG 3’ 
SH-4 Sense 5’  GTAG CAT ATG CTG GAT GCC CTG TTC GAC3’ 
Antisense 5’ GTAG CTC GAG TTA GTT GCT AAC ACC CTG 3’ 
SH-5 Sense 5’ GTAG CAT ATG TAC GGA GAA GAA ATC TAC C  3’ 
Antisense 5’ GTAG CTC GAG TTA GTT GCT AAC ACC CTG 3’ 
SH-6 Sense 5’ GTAG CAT ATG  GAA AAA TCG GTG GCC CTG 3’ 
Antisense 5’ GTAG CTC GAG TTA GTT GCT AAC ACC CTG 3’ 
SH-7 Sense 5’  GTAG CAT ATG  AAA AAA GTG CTG AAA GTT GTG 3’ 
Antisense 5’ GTAG CTC GAG TTA GTT GCT AAC ACC CTG 3’ 
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3.2.5 Overexpression of full length and truncated P. vivax DXS 
 
Both full length and truncated fragment of P. vivax DXS were expressed in E. coli 
BL-21 B(DE3) cells. A fresh colony of E. coli containing the appropriate plasmid was 
cultured at 37 
o
C in LB broth containing 100 µg/ml ampicillin for SH-1 and 50 µg/ml 
kanamycin for SH-2 to SH-9 supplemented with 0.8% glucose and 25mM potassium 
phosphate (pH = 7.2), was grown for 2-3 hours until OD600 reached ~ 0.3. Culture was 
then diluted 100- fold and cultured at 37 
o
C until OD600 reached ~ 0.6 and then cooled 
down to 25 
oC. Expression was induced by the addition of 0.5 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG), after shaking for 5-6 hours cells were harvested by 
centrifuged at 6,000g for 10 min. at 4
o
C and finally stored at -80 
o
C before purification.  
 
3.2.6 Ni-NTA Affinity chromatography purification  
 
Cells were thawed and all the purification steps were performed at 4
o
C. Cells 
were resuspended in binding buffer (20 mM Tris, 500 mM NaCl, 20 mM Imidazole, 10 
SH-8 Sense 5’ GTAG CAT ATG  CCG CTG CTG CGT CTG ATC 3’  
Antisense 5’ GTAG CTC GAG TTA GTT GCT AAC ACC CTG 3’ 
SH-9 Sense 5’ GTAG CAT ATG  GGT GGC CAC TTT TCC GCT 3’ 
Antisense 5’ GTAG CTC GAG TTA GTT GCT AAC ACC CTG 3’ 
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mM β-Me, pH = 7.5) supplemented with 1 mM phenylmethanesulfonylfluoride (PMSF), 
4 µg/mL leupeptin, 2 µg/mL pepstatin , sonicated using Heat systems W-380 ultrasonic 
processor, and centrifuged at 16,000g for 20 min. to remove cell debris. The supernatant 
from the cell lysate was applied to Ni-NTA resin (1.5 cm x 5 cm) which had been 
equilibrated with binding buffer at rate of 1mL/min and non-bound proteins eluted from 
the column by first washing with 5 column volume of binding buffer followed by 20 
column volume of wash buffer (20 mM Tris, 500 mM NaCl, 60 mM Imidazole, 10 mM 
β-Me, pH = 7.5). DXS SH-1 and SH-2 was eluted using elution buffer (20 mM Tris, 500 
mM NaCl, 250 mM Imidazole, 10 mM β-Me, pH = 7.5) and fractions containing protein 
were concentrated for gel filtration chromatography. 
 
3.2.7 Gel filtration chromatography purification of SH-2 construct 
 
Gel filtration chromatography was performed on a 2.5 x 90 cm Pharmacia 
Sephadex G-200 column. Column was calibrated with Apoferritin (400 kDa), β-Amylase 
(200 kDa), Alcohol dehydrogenase (150 kDa), Bovine serum albumin (66 kDa), and 
Carbonic anhydrase (29 kDa) at the rate of 0.5 mL/min with buffer containing 50 mM 
Tris (pH = 7.5), 150 mM NaCl, and 10 mM β-ME. The void volume for the column was 
calculated using Blue Dextran 2000. Affinity purified construct SH-2 was loaded on the 
column and fractions were collected (recording A280). Fractions with positive DXS 
activity were pooled together and concentrated to 1 mg/mL using 10 kDa Amicon ultra 
centrifugation filter. The molecular mass of recombinant P. vivax DXS SH-2 construct 
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was determined from a plot of the molecular mass (log Mr) versus the ratio of elution 
volume to void volume (Ve/Vo). Final yield from the expression was 1 mg/L of culture. 
Enzyme was flash frozen in liquid nitrogen, stored at -80
o
C and the purity was judged by 
SDS-PAGE.  
 
3.2.8 Determination of D-GLP concentration 
 
D,L-GLP was obtained from Sigma Aldrich as a suspension in water. 
Concentration of D-GLP was measured spectrophotometrically glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). A reaction mixture (0.5mL) containing 30 mM 
Sodium pyrophosphate buffer (pH = 8.6), 5 mM L-cysteine, 0.6 mM NAD
+
, 0.6 mM 
Sodium arsenate, and D,L-GLP at concentration less than 0.2 mM were incubated at 30 
o
C for 10 min, the reaction initiated with 2µg GAPDH (Novus Biotechnology) and the 
progress of the reaction monitored spectrophotometrically at 340 nm. The final 
concentration of D-GLP was calculated based on the production of NADPH (ε340 = 6,220 
M
-1
cm
-1
).  
 
3.2.9 Preparation of Apo-DXS SH-2 
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Apo-DXS SH-2 was prepared using a modified procedure (Wang, Martin and 
Singleton 1997, Meshalkina et al. 2010). Briefly, 0.5 mg/mL of DXS SH-2 in buffer 
containing 50 mM Tris (pH=7.5), 150 mM NaCl, and 10 mM β-ME was resuspended 
with saturated ammonium sulfate, 5 mM TCEP, pH = 3.5 at ratio of 2:3, and kept on ice 
for 20 min. After incubation, the mixture was centrifuged at 12,000g for 10 minutes and 
the pellet was resuspended in buffer containing 50 mM Tris (pH = 7.5), 150 mM NaCl 
and 2mM TCEP. Removal of TPP and Mg
2+
 was monitored by assaying for DXS activity 
using DXS-DXR coupled assay (section 3.2.10). 
 
3.2.10 DXS-DXR coupled assay  
 
The DXS-DXR coupled assay solution consists of 100 mM HEPES buffer (pH = 
7.0), 100 mM NaCl, 1 mg/ml BSA, 1 mM thiamine pyrophosphate (TPP), 1.5 mM 
Magnesium chloride (MgCl2), 2 mM β-Me or 2 mM TCEP, 0.15 mM NADPH, 0.2 
mg/ml DXR, and varying concentration of pyruvate or D-GLP. Steady-state kinetics 
studies were performed by varying pyruvate and D-GLP at fixed concentration of the co-
substrate. A DXS-DXR reaction solution was incubated at 37 
o
C for 5 min, the reaction 
was initiated by addition of 96.2 nM P. vivax DXS SH-2, and the progress of the reaction 
was monitored at 340 nm for the consumption of NADPH. NADPH consumption directly 
corresponds to the production of DXP. Assays were performed in triplicate and the data 
was fitted using equation 1 as discussed in section 3.2.12 to calculate the steady-state 
kinetic parameters.  
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3.2.11 DXS HPLC assay  
Non-continuous DXS assay was performed in a 0.25 mL reaction mixture 
consisting of 100 mM HEPES buffer (pH = 7.0), 80 mM NaCl, 1 mg/ml BSA, 2 mM β-
Me, 5 mM Magnesium chloride (MgCl2), 1 mM thiamine pyrophosphate (TPP) and 
varying concentration of pyruvate, D-GLP and fixed concentration of co-substrate were 
incubated at 37 
o
C for 5 min. Reaction was initiated by addition of 192.6 nM of P.vivax 
DXS SH-2, and at the desired time, an aliquot (50 µL) was removed and quenched into 
equal volume of cold methanol, and incubated at 4°C for 20 min. Samples were 
centrifuged and a 50 µL aliquot of the supernatant was incubated with equal volume of 
2,4-DNP reagent (100 mM 2,4-DNP in 2N H2SO4). After a 5min. incubation, the pH was 
adjusted to 5-7 by addition of 36 µL 4M Tris buffer (pH = 10.0), and then centrifuged to 
remove excess 2,4-DNP. Samples were stored at -20
o
C before HPLC analysis. The DNP 
derivatives of pyruvate, D-GLP, and DXP were separated using a 5 µm Discovery
®
 C18 
column (25 cm × 4.6 mm) developed using the following conditions:  flow rate = 1.5 
mL/min; solvent A, 100 mM ammonium acetate, 0.05% TFA (pH = 4.6); solvent B, 
acetonitrile, 0.05% TFA; 20% - 35% solvent B over 12 min and then 35 – 60% solvent B 
over 2 min. In case of pyruvate at fixed concentration of D-GLP concentration (0.25 
mM), DXP hydrazone peak area (DXP production) was measured and the concentration 
was determined by standard curve of DXP hydrazone. Assay was performed in triplicate 
and the data was fitted and analyzed using equations discussed in section 3.2.12.  
 
 
94 
 
3.2.12 Equation for analyzing the kinetic data 
 
The steady state initial velocity for DXS measured at various concentrations of 
pyruvate and D-GLP were fit to eq 7 using nonlinear regression analysis in Sigma-Plot 
12.0  
  
Equation 7 
 
3.2.13 Inductively coupled plasma mass spectrometry (ICP-MS) for Mg
2+
 estimation 
 
Magnesium ion content in P. vivax DXS SH-2 was determined using Perkin 
Elmer Elan II quadrupole inductively coupled plasma-mass spectrometer (ICP-MS). 
Instrument was calibrated using 1, 20, 60, and 100 ppb Mg
2+
 standard solution. Enzyme 
sample was diluted to 0.05 mg/mL corresponding to a concentration of 414 nM and was 
used further with no modification. Experiment was repeated in duplicate.  
 
 
 
 
 
ν  =
𝑽𝒎𝒂𝒙 [𝐒]
𝑲𝒎 +[𝑺]
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3.3 Results and Discussion 
 
3.3.1 Cloning and expression of full length P.vivax DXS using genomic DNA  
 
Malaria is the most neglected of all human diseases and it is estimated that 
approximately 50 % of the world population were at the risk of malaria in 2010 (WHO 
2010). Global problem in malaria and other neglected diseases such as tuberculosis, 
leishmaniasis, and trypanosomaiasis can be addressed by research in the development of 
drugs targeting novel pathways. But, due to low return on the investment all the 
pharmaceutical companies haven’t been keen to address this issue. A recent amendment 
act of 2007 by the Food and Drug Administration (FDA) is giving an opportunity to 
companies to apply for a “voucher” to expedite the FDA review of any drug made by the 
company, given the condition of promotion to develop pharmaceutical products for 
neglected diseases (Kesselheim 2008). All the current antimalarial chemotherapeutics 
targets the asexual stages of parasite and more specifically the pathways that exists in 
cytosol, food vacuole, mitochondria, parasite membrane and apicoplast (Rosenthal 2003, 
Sahu, Sahu and Kohli 2008).  
 
It has been reported previously by Cassera et al., that the non mevalonate pathway 
is functionally active in all intraerythrocytic stages of P.falciparum (Cassera et al. 2004), 
and none of the enzymes from this pathway has homologues enzymes in mammals, thus 
96 
 
making  this pathway as an unexplored territory for the development of antimalarial drug. 
The complete genome sequencing of P. vivax has further confirmed the presence of 
proteome of the NMVA, with the presence of bipartite N-terminal sequence for 
apicoplast targeting (Carlton et al. 2008).  So, far there have been two reports on the 
expression of enzymes involved in NMVA in P. falciparum. In the first report, DXR the 
second enzyme of the NMVA pathway without the signaling and transit peptide has been 
expressed in E. coli as inclusion bodies and further refolded to regain the active enzyme 
(Jomaa et al. 1999). The other report involves the expression of P. falciparum IspF, 
which express as inclusion bodies when expressed as full length enzyme. When IspF was 
expressed as truncated protein (without signaling and transit peptide), it was expressed as 
soluble homogenous protein with only 5% maximum catalytic activity as compared to E. 
coli homolog (Rohdich et al. 2001). Study done in this report presents a first novel 
example of expression of soluble, homogeneous and active P. vivax DXS. 
 
Open reading frame on the reverse complement of nucleotide sequence from 
693,715 to 697,050 on chromosome 12 of P. vivax Sal-1 was PCR out using genomic 
DNA (Figure 3.3). The P. vivax dxs gene flanked by the engineered in BamHI and 
HindIII restriction sites was cloned into the pET21b(+) vector with a C-terminal His6 tag. 
Occurrence of rare codon in high frequency is one of the challenging problems of protein 
expression in E. coli and in P. vivax dxs gene it accounts for about 9.1%. The rare codon 
frequency and occurrence of tandem repeat of rare doublet and triplet codon (total 102 
out of 1112 codons) could makes the expression of this protein very difficult. In order to 
overcome this barrier Rosetta B(DE3) cell line was used. This cell line provides the 
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tRNA for the rare codon (Arg-AGG, AGA, CGA, Leu-CTA, Pro-CCC, Ile-ATA) which 
are in low abundance in E. coli.  
 
 
 
 
 
 
 
 
 
Figure 3.3: (A) P. vivax dxs gene encoded on chromosome-12 (highlighted in yellow 
color), (B) DNA gel showing- Marker (lane 1) and P. vivax dxs gene isolated using 
genomic DNA as template (lane 2). 
 
After, confirming the DNA sequence, the pET21b(+)-vivax-DXS vector was used 
to transform E. coli strains, BL-21 B(DE3) and Rosetta B(DE3). Recombinant DXS was 
purified using Ni-NTA resin as described in section 3.2.6. The final DXS produced as 
described herein was ~70-80 % pure as judged by SDS-PAGE (Figure 3.4). The final 
yield of 40µg of partially purified enzyme / L of culture from BL-21 cells and 80µg using 
Rosetta B(DE3) cell line was obtained. This full length P. vivax DXS was active and 
 
98 
 
specific activity of the 70% pure protein (0.9 ± 0.1 µmoles/min/mg) was comparable to 
the value with D. rad DXS (5.6 µmoles/min/mg). 
 
 
 
 
 
 
 
 
Figure 3.4: SDS-PAGE analysis of P.vivax DXS in E.coli. MW standard (lane 1), cell 
lysate (lane 2), Flow through from Ni-NTA resin (lane 3), binding buffer wash (lane 4), 
wash buffer wash (lane 5), and purified P.vivax DXS (lane 6). 
 
 
3.3.2 Cloning and expression of full length P.vivax DXS using codon optimized DNA 
 
Expressions of protein/enzyme from plasmodium species in E. coli have always 
been hard, and most of the time it ends up in an inclusion bodies. But in case of P. vivax 
DXS, we can use the result from the expression of this enzyme from genomic DNA as a 
proof of concept that this enzyme can be expressed functionally active in E. coli with no 
formation of inclusion bodies. In order to overcome the effect of high rare codon 
frequency in genomic DNA and low expression yield, gene for the P. vivax DXS was 
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codon optimized (Genescript) for expression in E.coli. Initial analysis of the dxs gene 
revealed other factor such as cis-acting element (ribosome binding site, poly A and poly 
T) apart from high rare codon frequency which could have hindered the expression of dxs 
 
 
 
 
 
 
 
 
gene (Sharp and Li 1987). In total there were total of six E. coli ribosome binding site 
(AGGAGG), two poly-A (AAAAAA), and two poly-T(TTTTTT) were found in the dxs 
gene. Synthetic P.vivax dxs gene with high codon adaptive index (0.89) and without the 
cis-acting element was optimized for expression in E.coli and supplied in pUC 57 vector 
with gene flanked by 5’-NdeI and 3’-HindIII restriction sites (Figure 3.5) 
 
Codon optimized P. vivax dxs gene in pUC 57 vector obtained from Genescript 
was cloned in pET21b(+) vector using NdeI and HindIII  restriction site. After sequence 
 
Figure 3.5: pUC 57 vector with codon optimized 
P. vivax dxs gene. 
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confirmation the pET21b(+)-SH-1 vector was transformed into BL-21 B(DE3) cell line, 
and P. vivax DXS was expressed and purified as discussed in section 3.2.3. Expression of 
full length P.vivax DXS which includes both signal and transit peptide always yielded a 
truncated protein along with full length protein (Figure 3.6) with an overall yield of ~1.5 
mg per L of culture (~18 fold more than the vector pET21b(+)-vivax-DXS). Various 
conditions such as induction temperature, protease inhibitor, induction time, and IPTG 
concentration were tried to avoid this truncation of full lenght protein, but it cannot be 
avoided. 
 
 
 
 
 
Figure 3.6: SDS-PAGE analysis of P. vivax DXS SH-1 in E. coli. MW standard (lane 1), 
cell lysate (lane 2), Flow through from Ni-NTA resin (lane 3), binding buffer wash (lane 
4), wash buffer wash (lane 5), and Elution P. vivax DXS (lane 6-9). 
 
3.3.3 Cloning and expression of truncated P. vivax DXS  
 
To overcome the problem of full length protein truncation, the next step used was 
to express the P. vivax DXS without the nuclear encoding region (signaling and transit). 
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All the enzymes involved in the non mevalonate pathway are nuclear encoded (Figure 
3.2), but transported to the apicoplast for the expression of the enzyme (Hunter 2007). 
Recent discovery of the apicoplast targeting enzymes and the role of signaling and transit 
peptide in transportation and folding of gene from nucleus to apicoplast are still not clear. 
Based on the sequence of protein functionally active in apicoplast, set of rules have been 
defined to characterize the apicoplast targeting proteins: (a) starts with signal peptide, (b) 
a stretch of 40 amino acids with at least nine asparagines and/or lysines residues after the 
signal cleavage site, (c) ratio of basic residues to acidic residues in aspargine/lysine-
enriched region to be at least 5 to 3 (Foth et al. 2003). Over the year many software has 
been developed to predict the apicoplast targeting protein and cleavage site between 
signal and transit peptide, and using these web based tools predicts similar results with 
size ranging approximately from 25-30 amino acids (Table 3.3). 
Table 3.3: Predicted cleavage site between signal and transit peptide.  
Software 
used 
N-terminal Sequence (cleavage 
site highlighted)  
Expected Size  Reference 
SignalP MIMGTSSLLLLLALIITSMHV 
SLNAASGKCEV 
25 (Petersen et al. 
2011b) 
PSORT MIMGTSSLLLLLALIITSMHV 
SLNAASGKCEV 
30 (Nakai and 
Kanehisa 1992) 
PATS MIMGTSSLLLLLALIITSMHV 
SLNAASGKCEV 
23 (Zuegge et al. 
2001) 
PlasmoAP MIMGTSSLLLLLALIITSMHV 
SLNAASGKCEV 
25 (Foth et al. 2003) 
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 Transit peptide cleavage site from mature protein upon transportation to the apicoplast is 
still unanswered, and it’s difficult to develop software to predict the cleavage site because 
the transit peptide can vary from around 24 to over few hundreds amino acids and have 
no conserved sequence motifs when compared to the apicoplast targeting proteins. As a 
control, sequence of DXS from Plasmodium species were compared and aligned to get a 
better picture of transit peptide (Figure 3.7) and the comparison of 200 amino acids from 
N-terminal, showed no sequence homology and identity. Showing that even the same 
enzyme from different plasmodium species shares no correlation in transit peptide 
sequence. A recent study using transit peptide of acyl carrier protein from P. falciparum, 
it has been proposed that transit peptide is either low occupancy helix or disordered both 
in-vivo and in-vitro (Gallagher, Matthews and Prigge 2011), and upon introduction of 
ordered structure through mutation, the ability of peptide to translocate to apicoplast was 
lost. 
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Figure 3.7: N-terminal Sequence (~400 amino acid) comparison of DXS from P. berghei, 
P. yoeli, P. falciparum, P. vivax, and P. knowlesi. 
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In order to express the soluble and active P. vivax DXS without the signaling and 
transit peptide, sequence of E. coli, D. rad and P. vivax DXS were compared to 
understand the cleavage site between transit peptide and mature protein. Clone SH-7 to 
SH-9 (Table 3.4) were designed first based on high sequence similarity with E. coli and 
D. rad DXS using the same analogy as used for the expression of DXR from P. 
falciparum (Jomaa et al. 1999).   
Table 3.4: N-terminal amino acid truncation for SH-2 to SH-9. 
Clone Name N-terminal amino acids truncated  
SH-2 210 
SH-3 245 
SH-4 252 
SH-5 272 
SH-6 303 
SH-7 347 
SH-8 357 
SH-9 395 
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Figure 3.8: Clustal W2 alignment of E. coli, D. rad. and P. vivax DXS, and showing the 
truncation site for P. vivax DXS. 
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Figure 3.8: Continued 
 
 
 
Deletion of 347 to 395 amino acids from N-terminal to generate clone SH-7 to 
SH-9 respectively, yield a soluble but in-active enzyme. Therefore amino acids from N-
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terminal were sequentially removed to achieve homogenous and active enzyme (Figure 
3.9). Alignment of DXS from different species and between the plasmodium species 
shows that sequence between amino acid 200 and 395 shares a high homology between 
plasmodium species (Figure 3.7 and 3.8). Sequential deletion led to the generation of 
clone SH-2, which was expressing soluble, homogenous and active protein in good 
yields. 
 
 
 
 
 
 
 
Figure 3.9: DNA gel showing cloned vector digested with NdeI and XhoI restriction 
enzymes. Marker (lane-1), SH-1 (lane-2), SH-2 (lane-3), SH-3 (lane-4), SH-4 (lane-5), 
SH-5 (lane-6), SH-6 (lane-7), SH-7 (lane-8), SH-8 (lane-9), and SH-9 (lane-10). 
 
 
 
3.3.4 Purification of P. vivax DXS SH-2 
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P. vivax DXS clone SH-2 was overexpressed in E. coli BL-21 B(DE3) cell line. 
Due to the instability of plasmid at high cell density, cells were always kept OD600 < 0.8 
before expression. Along with this, cells were supplemented with 0.8% glucose and 25 
mM potassium phosphate buffer (pH = 7.2) to overcome the toxicity of plasmid in cells. 
Affinity chromatography was used as a first step of purification and final yield observed 
after this step was 2.5 mg per liter of culture (Figure 3.10). All the active fractions from 
this step were pooled together, concentrated (8mL with 5% glycerol) and loaded on to gel 
filtration column (Sephadex G-200), which was previously been calibrated with  
 
 
 
 
 
 
 
Figure 3.10: SDS-PAGE analysis of P.vivax DXS SH-2 affinity purification. MW 
standard (lane 1), uninduced control (lane 2), cell lysate (lane 3), flow through the Ni-
NTA resin (lane 4), wash (lane 5), elution of P. vivax DXS SH-2 (lane 6-9). 
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apoferritin, β-amylase, alcohol dehydrogenase, bovine serum albumin, and carbonic 
anhydrase. Fractions from gel filtration column were checked for DXS activity using 
DXS-DXR coupled assay. The first peak with higher A280 value was found to have no or 
very little activity and based on standard calibration this peak might corresponds to either 
inactive tetramer of DXS or high molecular weight aggregate. Second peak with 
relatively lower A80 value gave the highest activity of DXS and probably exists as dimer 
(Figure 3.11 and 3.12). DXS from R. capsulatus and D. rad have also been reported 
previously to exist as dimers (Hahn et al. 2001, Xiang et al. 2007) 
 
 
 
 
 
 
 
 
 
Figure 3.11: Gel filtration chromatography of P. vivax DXS SH-2 on Sephadex G-200 
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Figure 3.12: Determination of the molecular mass of P. vivax DXS SH-2 by gel filtration 
chromatography. 
 
Active fractions peak from gel filtration column were pooled (1/3 of the peak 
height) and concentrated to 1mg/mL and used for further characterization. SDS-PAGE 
and western blot analysis of the affinity column and gel filtration column showed that P. 
vivax DXS SH-2 was >95% pure and homogenous (Figure 3.13). After separation of high 
molecular weight aggregate or inactive tetramer, the final yield of purified enzyme was 
around 1 mg per L of E. coli cultures. This yield was lower as compared to the expression 
yield of D. rad DXS (7-8 mg per L of culture), where also codon optimized gene was 
used for the expression. This relatively low yield could be due to relatively high 
molecular weight of the P. vivax DXS (~104 kDa) as compared to D. rad DXS (69.9 
kDa) and around 60% of the expressed protein was found out to be inactive after gel 
filtration chromatography. 
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Figure 3.13: (A) SDS-PAGE analysis of P. vivax DXS SH-2: MW standard (lane 1), 10 
µg of affinity purified enzyme (lane 2), and 10 µg of gel filtration purified enzyme. (B) 
Western blot analysis of P. vivax DXS SH-2: 1 µg of gel filtration purified enzyme (lane 
1), 1 µg of affinity purified enzyme (lane 2), and MW standard (lane 3). 
 
3.3.5 Characterization of P. vivax DXS SH-2 
 
Homogeneously purified P. vivax DXS SH-2 was further used for 
characterization. DXS-HLPC assay was used for the determination of pH optimum of the 
reaction catalyzed by DXS at saturating concentration of pyruvate and D-GLP. Optimum 
pH for the P. vivax DXS SH-2 was found out to be between 7-7.5 (Figure 3.14), which is 
comparable to DXS from R. capsulatus (7.0) and E. coli (8.0) (Hahn et al. 2001, 
Brammer and Meyers 2009).  
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Figure 3.14: pH optimum determination of P.vivax DXS SH-2 using HPLC assay 
 
DXS need TPP and divalent metal ion (Mg
2+
 or Mn
2+
) for catalytic activity. In 
order to understand the binding of divalent metal ion and the concentration required to 
achieve maximum activity, enzyme activity was checked in absence of divalent metal 
ion. We observed that the enzyme was completely active even in absence of any metal 
ion and same observation was seen for TPP. Even though no external source of TPP and 
Mg
2+ 
was used during culturing and purification, suggesting that P. vivax DXS SH-2 used 
TPP and Mg
2+ 
cofactors from the media (LB broth) used for culturing and are very tightly 
bound.  
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To remove the bound TPP and Mg
2+ 
from enzyme, it was dialyzed in presence of 
EDTA, and was found that even after dialyzing the enzyme in presence of EDTA, we 
found that enzyme was completely active in absence of TPP and Mg
2+
. Protocol used to 
remove the tightly bound cofactors was adopted from the method used to remove TPP 
from transketolase (Wang et al. 1997, Meshalkina et al. 2010). Incubation of enzyme 
with saturated ammonium sulfate at lower pH (3.5), lead to complete removal of TPP 
with high recovery upon reconstitution, but Mg
2+
 was still bound to the enzyme as 
observed by active enzyme in absence of Mg
2+ 
using HPLC assay. Activity of the enzyme 
was reconstituted back upon addition of TPP (Figure 3.15). Inclusion of 5mM EDTA in 
this method however, led to the degradation of enzyme with only 25 % recovery, 
indicating that Mg
2+ 
plays crucial role in folding and absence of it causes the enzyme to 
be insoluble.    
 
 
 
 
 
Figure 3.15: Steady state kinetics of P. vivax DXS SH-2 upon reconstitution with TPP 
Inductively coupled plasma resonance mass spectrometry (ICP-MS) was then 
used to quantify the amount of Mg
2+ 
in enzyme. Molar ratio of Mg
2+ 
to DXS was found 
out to be 0.97 ± 0.01, which is approximately 1:1. These results suggests that Mg
2+
 is 
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bound more tightly than TPP and replacement of this tightly bound Mg
2+ 
with other 
divalent metal ion (Mn
2+
, Co
2+
 and Ca
2+
) could only be achieved by culturing the cells in 
minimal media with the respective divalent metal ion. 
 
Steady state kinetic parameters for pyruvate and D-GLP for P. vivax DXS SH-2 
were calculated using DXS-DXR coupled assay and are comparable with value from D. 
rad and E. coli DXS (Table 3.5 and 3.6). Apparent Km value of pyruvate for P. vivax 
DXS SH-2 were slightly higher than the value from D. rad and E. coli, one of the reason 
for this behavior could be due to different pH optima of DXS in these organisms. 
Table 3.5: Comparison of steady state kinetic constants for pyruvate 
Organism pH Pyruvate
a 
Comment 
Km (mM)
 
Kcat (s
-1
) Kcat/Km (M
-1
s
-1
) 
P. vivax 7.0 0.87±0.11 9.5 ± 0.5 
1.09 ± 0.06 x 10
4
 
This study 
D. rad 8.0 0.28 ± 0.03 7.4 ± 0.3 
2.64 ± 0.01 x 10
4
 
Section 2.3.2 
R. capsulatus 8.0 0.61 ± 0.05 1.9 ± 0.1 
0.31 ± 0.02 x 10
4
 
(Hahn et al. 2001) 
a
Apparent kinetic constants were measured by varying the initial concentration of 
pyruvate at 0.1 mM D-GLP. 
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Table 3.6: Comparison of steady state kinetic constants for D-GLP 
Organism pH D-GLP
b 
Comment 
Km (mM)
 
Kcat (s
-1
) Kcat/Km (M
-1
s
-1
) 
P. vivax 7.0 0.019±0.004 10.9 ± 0.9 
5.74 ± 0.47 x 10
5
 
This study 
D. rad 8.0 0.05 ± 0.01 7.9 ± 0.4 
1.45 ± 0.08 x 10 
5
 
Section 2.3.2 
R. capsulatus 8.0 0.068 ± 0.001 1.9 ± 0.1 
2.79 ± 0.15 x 10
4
 
(Hahn et al. 2001) 
b
Apparent kinetic constants were measured by varying the initial concentration of D-GLP 
at 4.0 mM pyruvate. 
 
3.4 Summary 
 
Expression of plasmodium protein in E .coli has always been a challenging 
problem specially for the apicoplast targeting protein (Vedadi et al. 2007). There have 
been only two reports on the expression of enzyme involved in NMVA pathway from P. 
falciparum (Jomaa et al. 1999, Rohdich et al. 2001). This study presents the first report 
on the expression of P. vivax DXS in E. coli, where it is expressed as soluble and 
homogenous enzyme. This enzyme has been characterized in great detail and it behaves 
similar to DXS from other organisms. 
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Chapter 4: Conclusion and Future Directions 
 
4.1 Conclusion 
 
In this study, mechanism of reaction catalyzed by TPP and Mg
2+
 dependent DXS 
was studied, along with its potential role in development of novel antibiotics and 
antimalarial. DXS is the first and also the rate limiting enzyme in NMVA pathway. 
Presence of NMVA pathway in many human pathogens and parasites; and non-existent 
of any homologues enzymes of NMVA pathway in human opens a unique opportunity to 
develop inhibitors against the rising incidents of neglected human diseases.  
 
DXS reaction mechanism and substrate binding was studied using steady state 
kinetics, product inhibition, dead end inhibitor, and through rational mutant design. 
Family of TPP dependent enzyme mostly catalyzed the reaction through ping-pong 
mechanism. Previous reports using R. capsulatus and E. coli DXS, the reaction is 
predicted to be ordered sequential and random sequential mechanism respectively. In this 
report, using D. radiodurans DXS we were able to differentiate the mechanism to be 
random sequential mechanism. We observed that DXP inhibits the reaction catalyzed by 
DXS with inhibition constant in high micro molar range (Ki = 128 µM for pyruvate and 
Ki = 828 µM for D-GLP) with competitive against pyruvate and non-competitive with 
respect to D-GLP. DXP bind to the same enzyme pocket as does the pyruvate even 
though resembling more with D-GLP. Similar trend was observed with F-Pyr. Summing 
up all these results with a novel domain organization in DXS as discussed in section 
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2.1.4, it can be concluded that the enzyme exhibits striking difference in substrate binding 
as compared to other TPP dependent enzymes and follows random sequential 
mechanism. 
 
Expression of protein from apicomplexan such as Plasmodium, Cryptosporidium 
and Toxoplasmain in E. coli has always been a challenging problem especially for 
apicoplast targeting protein (Vedadi et al. 2007). It has been predicted that 10% of the 
plasmodium species protein are targeting to the apicoplast through secretory pathway. 
Translocation and folding of protein from nucleus to the apicoplast is through use of a 
bipartite N-terminal signaling and transit sequence is still unclear (Tonkin, Kalanon and 
McFadden 2008). All the enzymes required for the synthesis of isoprenoids have been 
shown to translocate to apicoplast, and opens up a new platform for the development of 
novel antimalarial (Carlton et al. 2008, Gardner et al. 2002). 
 
Present study deals with the expression of P. vivax DXS in E. coli. To overcome 
the expression problem due to codon bias and cis-acting element, dxs gene was codon 
optimized. Expression of P. vivax DXS without the signaling and transit sequence was 
the next challenging question. To answer this question, step wise deletion approach was 
used (section 3.3.3). Deletion of 210 amino acids from N-terminal led to the expression 
of soluble and active enzyme. Affinity and gel filtration chromatography was used to 
purify P. vivax DXS SH-2 clone to homogeneity. The purified enzyme was characterized 
and compared with DXS from other organisms. 
124 
 
4.2 Future Directions 
 
4.2.1 Lead compound for P. vivax DXS inhibition   
 
DXS catalyzes the rate-determining step of the NMVA pathway, and is required 
for the erythrocytic development of Plasmodium , and is positioned at the interface of 
two other critical metabolic pathways (Cassera et al. 2004). The product of the DXS 
reaction, is also required for biosynthesis of pyridoxal and thiamin (Müller, Hyde and 
Wrenger 2010). As a consequence, DXS is an attractive drug target. A DXS inhibitor 
given in combination with an inhibitor developed specifically to inhibit fatty acid 
synthesis in the apicoplast, a metabolic pathway crucial to hepatic development of 
Plasmodium (Tarun et al. 2008, Vaughan et al. 2009) could be a used as a powerful drug 
combination for the treatment of malaria. Such a drug combination would be lethal to the 
parasite and could exhibit limited human toxicity and would be less likely to evoke 
resistance in the parasite. A modern and interdisciplinary approach to identify lead 
compounds for the inhibition of P. vivax DXS could prove useful for novel antimalarial. 
 
Antimalarial compound libraries from GSK, Novartis, and St. Jude's Children's 
Research Hospital (encompassing over 300,000 compounds) can be used for virtually 
screening against the P. vivax DXS homology model build in collaboration with Dr. 
Guida’s lab. In addition, other commercially available chemical libraries like the ZINC 
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database (http://zinc.docking.org/) can also be virtually screened. Top hits for the virtual 
screen will then be screened for P. vivax DXS inhibition using DXS-DXR coupled assay. 
 
4.2.2 Crystal structure of P. vivax DXS 
 
Expression of proteins from Plasmodium species has always been challenging 
problem because of codon mismatch and toxicity of the protein with respect to the choice 
of host used for expression. According to protein data bank (pdb), till date there has been 
only 371 reports for P. falciparum and 52 reports for P. vivax on protein crystallization. 
These numbers are increasing at great rate because of the advancement in molecular 
biology. So, far there is only one report on the crystallization of an enzyme (DXR) of P. 
falciparum from NMVA pathway (Umeda et al. 2010). Study done in this report has 
successfully solved the first problem of expression of soluble and homogenous protein 
from P. vivax. The next step is to start the crystallization trial for this enzyme. A request 
has been submitted to “Seattle Structure Genomics for Infectious Disease” and P. vivax 
DXS is currently being screened to find the condition needed to obtain crystal. X-ray 
crystal structure of this enzyme will be helpful in rational drug design against these drug 
resistant malaria parasites. 
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Appendix-1 
 
Part A: Abbreviations 
IPP                      Isopentenyl pyrophosphate 
DMAPP              Dimethylallyl pyrophosphate 
MVA                   Mevalonate  
NMVA                Non Mevalonate 
HMGR                HMG-CoA reductase 
GLP                    Glyceraldehyde-3-phosphate 
DXS                    1-deoxy-D-xylulose-5-phosphate synthase 
DXR                    1-deoxy-D-xylulose-5-phosphate reductoisomerase 
IspD                     4-Diphosphocytidyl-2C-methyl-D-erythritol 4-phosphate synthase 
IspE                     4-Diphosphocytidyl-2C-methl-D-erythritol Kinase 
IspF                      2C-Methyl-D-erythritol 2,4 diphosphate synthase 
IspG                     2C-Methyl-D-erythritol 2, 4-cyclodiphosphate reductase 
IspH                     1-Hydroxy-2-methyl-butenyl 4-diphosphate reductase 
NADPH               Nicotinamide adeninedinucleotide phosphate reduced form 
 
DXP                     1-deoxy-D-xylulose-5-phosphate 
MEP                     2-C-methyl-D-erythritol 4-phosphate 
CMP                     Cytidine monophosphate 
HPLC                   High-performance liquid chromatography 
TPP                      Thiamine pyrophosphate 
TK                        Transketolase 
PDH                      Pyruvate dehydrogenase 
F-Pyr                     Fluoropyruvate 
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ICP-MS               Inductively coupled plasma mass spectrometry 
 
Part B: Figures 
 
 
 
 
 
 
 
 
 
 
Figure S-1: D. rad DXS wild type pyruvate Kinetics 
 
 
 
 
 
 
 
 
 
 
Figure S-2: D. rad DXS wild type D-GLP Kinetics 
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Figure S-3: SDS-PAGE analysis of DXS WT and mutants: Marker (lane 1), DXS WT 
(lane 2), H82A (lane 3), Y395F (lane 4), Y395A (lane 5), N181A (lane 6), N183A (lane 
7), R423A (lane 8), H434A (lane 9), D430A (lane 10), R423K (lane 11), and H304A 
(lane 12). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S-4: D. rad H82A DXS pyruvate Kinetics 
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Figure S-5: D. rad H82A DXS D-GLP Kinetics 
 
 
 
 
 
 
 
 
 
 
 
Figure S-6: D. rad Y395A DXS pyruvate Kinetics 
H82A D-GLP Kinetics
[D-GLP] (mM)
0.0 0.2 0.4 0.6 0.8 1.0 1.2
V
 (
µ
M
/m
in
)
0
2
4
6
8
10
Y395A Pyruvate Kinetics
[Pyruvate] (mM)
0.0 0.5 1.0 1.5 2.0 2.5
V
 (
µ
M
/m
in
)
0
10
20
30
40
50
60
70
133 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S-7: D. rad Y395A DXS D-GLP Kinetics 
 
 
 
 
 
 
 
 
 
 
 
Figure S-8: D. rad Y395F DXS pyruvate Kinetics 
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Figure S-9: D. rad Y395F DXS D-GLP Kinetics 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S-10: D. rad D430A DXS pyruvate Kinetics 
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Figure S-11: D. rad D430A DXS D-GLP Kinetics 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S-12: D. rad H434A DXS pyruvate Kinetics 
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Figure S-13: D. rad H434A DXS D-GLP Kinetics 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S-14: D. rad R423A DXS pyruvate Kinetics 
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Figure S-15: D. rad R423A DXS D-GLP Kinetics 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S-16: D. rad R423K DXS pyruvate Kinetics 
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Figure S-17: D. rad R423K DXS D-GLP Kinetics 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S-18: D. rad N181A DXS pyruvate Kinetics 
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Figure S-19: D. rad N181A DXS D-GLP Kinetics 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S-20: D. rad DXS wild type thiamine pyrophosphate binding kinetics 
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Figure S-21: E. coli DXR steady state kinetics with DXP 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S-22: D-GLP standard curve using dinitrophenyl hydrazine 
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Figure S-23: DXP standard curve using dinitrophenyl hydrazine 
 
 
 
 
 
 
 
 
 
 
 
Figure S-24: D. rad DXS wild type pyruvate kinetics using DNP assay 
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Figure S-25: Lineweaver-Burk plot of D. rad DXS wild type pyruvate kinetics using 
DNP assay 
 
 
 
 
 
 
 
 
 
 
Figure S-26: D. rad DXS wild type D-GLP kinetics using DNP assay 
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Figure S-27: Lineweaver-Burk plot of D. rad DXS wild type D-GLP kinetics using DNP 
assay. 
 
 
 
 
 
 
 
 
 
 
 
Figure S-28: Mutagenesis by overlap extension method employs the polymerase chain 
reaction (PCR) as a mean of altering the DNA. This technique can be used for the 
generation of site specific mutants and insertion or deletion in the cloned gene with 
greater efficiency in few steps.  
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Appendix-2 
 
Production of the Catalytic Core of Human Peptidylglycine α-Hydroxylating 
Monooxygenase (hPHMcc) in Escherichia coli 
 
1. Introduction  
 
Approximately 50% of all mammalian peptide hormones possess an α-amidated  
C-terminus, which is required for bioactivity [1,2].  The α-amidated peptides are 
produced by the oxidative cleavage of C-terminal glycine-extended precursors to 
generate the α-amidated peptide and glyoxylate [3,4].  The enzyme catalyzing this 
reaction is bifunctional peptidylglycine α-amidating monooxygenase (PAM).  
Bifunctional PAM is comprised of two separate catalytic units, peptidylglycine -
hydroxylating monooxygenase (PHM, EC 1.14.17.3) and peptidylamidoglycolate lyase 
(PAL, EC 4.3.2.5) (Figure. 1) [5-7].  The PAM/PHM/PAL enzyme system represents a 
significant impediment to the manufacture of therapeutically important α-amidated 
peptides. The large-scale, inexpensive production of recombinant α-amidated peptides 
has been thwarted by difficulties in the bacterial expression of PAM, PHM, or PAL.  The 
only reported success in bacteria has been the co-expression of rat PAM with the glycine-
extended calcitonin or glucagon in Streptomyces to yield the desired α-amidated peptide 
[8-10].  Methods to circumvent this limitation for α-amidated peptide production include 
the use of PAM in vitro to amidate recombinantly produced glycine-extended peptides 
[11-15], the overexpression of a glycine-extended peptide in mammalian cells that 
145 
 
express PAM [16-19], the expression of a suitable peptide precursor that is chemically 
converted to the α-amidated peptide in vitro [20-23], transacylation/transpeptide methods 
[24-27], production in the milk of transgenic rabbits [28], and an intein based method 
[29].   
 
The expression of mammalian proteins in E. coli is often limited by (a) large differences 
in codon frequencies between mammalian and E. coli proteins, (b) the inability of E. coli 
to properly carry out the post-translational modifications found in many mammalian 
proteins, and (c) the formation of insoluble inclusion bodies.  In order to overcome such 
problems for the E. coli expression of human PHM, we utilized a synthetic gene coding 
for the catalytic core of human PHM (hPHMcc), which was optimized for E. coli 
expression. Kolehkar et al. [30] have shown that amino acids 42-356 of rat PHM retained 
the catalytic properties of the full length enzyme.  The two putative N-linked 
glycosylation sites, Asn-411 and Asn-762, within are absent in hPHMcc [31], which 
should aid in the expression of active enzyme.    We evaluated a series of fusion partners, 
glutathione-S-transferase (GST), thioredoxin (Trx), N utilization substance A (NusA), 
maltose binding protein (MBP), and a His6 tag, for the expression of active, soluble 
hPHMcc.  We report herein on the successful expression of a Trx-hPHMcc-His6 fusion 
protein that exhibits steady-state kinetic parameters similar to that of wildtype rat 
PHMcc. 
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2. Materials and methods 
 
2.1 Materials 
 
BamHI, HindIII, Antarctic Phosphatase, pMAL-c2X, and T4 DNA ligase were purchased 
from New England Biolab. Goat polyclonal anti-PAM monoclonal antibody (sc-17393), 
sheep anti-goat IgGs, and horseradish peroxidase were purchased from Santa Cruz 
Biotechnology. Oligonucleotides were obtained from Integrated DNA Technologies. Ni-
NTA resin, pET21a(+), pET32a(+), pET42b(+), pET43.1a(+) vectors, and the E.coli 
strains BL 21 (DE3) and Origami B(DE3) were purchased from Novagen (Table S1, 
supplementary material). Protease inhibitor cocktail and N-dansyl-Tyr-Val-Gly were 
purchased from Sigma-Aldrich. Ampicillin sodium salt, carbenicillin, IPTG was 
purchased from Fisher Scientific.  All other reagents were of the highest quality available 
from commercial suppliers. 
 
2.2 Molecular Cloning 
 
The DNA sequence for the hPHMcc gene was codon optimized for expression in E. coli 
and commercially synthesized by the GeneArt (www.geneart.com).  Based on the 
sequence of human PAM (accession no.  P19021), the coding region from amino acid 40 
to 454 was supplied in the pGA4 vector.  This coding sequence was amplified by PCR 
with pGA4 as a template (primers, forward 5’-
CATGGGATCCATGAACGAATGCCTGGGTAC-3’, reverse 5’-
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ATGAAGCTTTTAAATCGGAATATTCGCTTCCG-3’) and cloned into the pET 
vectors using the BamHI and HindIII restrictions site. Sequences of the cloned vectors 
were confirmed by DNA sequencing from MWG Operon. The recombinant plasmid was 
transformed into the different E. coli strains (Novagen) for expression. Co-expression 
experiments were performed using the chaperonin Plasmid Set (Takara Bio USA) 
containing the plasmids pG-KJE8, pGro7, pKJE7, pG-Tf2 and pTf16.  E. coli Origami 
B(DE3) cells were transformed with pET32a-hPHMcc vector, made competent 
chemically, and the competent E. coli Origami B(DE3)-hPHMcc cells were transformed 
with each plasmid possessing a chaperonin gene.   
 
2.3 Culture Cultivation 
 
 An overnight culture of E. coli bearing pET32a-hPHMcc was diluted 100 fold 
in LB medium supplemented with 100 µg/ml carbenicillin and 1% glucose and cultured 
at 37 °C. The culture was cooled down to 10 °C, was induced with IPTG (final 
concentration = 100 µM) when the OD600 reached 0.6, and incubated for another 4 hrs. 
The cells were collected by centrifugation at 10,000 rpm for 10 min and stored at -80 °C. 
 
2.4 Protein Purification 
 
 All the purification steps were performed at 4 °C. The cell pellet was 
resuspended in Buffer A (20 mM Tris, 500 mM NaCl, and 20 mM imidazole, pH 7.8) at 
to a concentration of 0.1 g/ml, with 1 mg/ml lysozyme and protease inhibitor cocktail 
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added according to the manufacture's instruction.  Resuspended cells were sonicated and 
the cell lysate collected by centrifugation at 16,000 × g for 20 min. The pelleted cell 
lysate was resuspended with Ni-NTA resin equilibrated in buffer A for 2 hr.  Resin was 
then loaded into a column and washed with 10 column volumes of buffer A.   Next, the 
Ni-NTA column was washed with 10 column volumes of buffer B (20 mM Tris, 500 mM 
NaCl, 1M guanidine hydrochloride, and 60 mM imidazole, pH 7.8), and then with 20 
column volumes of buffer C (20 mM Tris, 500 mM NaCl, and 60 mM imidazole, pH 
7.8). Recombinant hPHMcc was eluted from the Ni-NTA column using a linear gradient 
of 60 to 140 mM imidazole in buffer C.  The fractions containing hPHMcc activity was 
pooled and concentrated using YM-10 centriprep ultrafilter. The active fractions were 
concentrated to 0.5 mg/ml and stored at -20 
o
C. 
 
2.5 Expression and Analysis by Mass Spectrometry 
 
 We evaluated the E. coli constructs for hPHMcc expression by Western blot 
analysis.  After induction, 5 ml was withdrawn from the culture at 1 hr interval, 
centrifuged to collect the cells, lysed using lysozyme, and evaluated using SDS-PAGE.  
Expression of hPHMcc was confirmed by Western blot using an anti-PAM antibody and 
compared it to an uninduced control.   
 
 After SDS-PAGE, the Comassie stained protein band corresponding to the 
correct mass for hPHMcc or the hPHMcc fusion proteins was extracted from the gel and 
the protein digested using restriction grade trypsin. A Hybrid linear ion trap-Orbitrap 
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(LTQ Orbitrap XL, Thermo) mass spectrometer equipped with an Eksigent NanoLC-
Ultra 2D Plus HPLC system was used for the analysis of the tryptic fragments. 
 
2.6 Activity Assay 
 
    
hPHMcc activity was assayed using a modification of a published procedures [32,33]. 
Briefly, the reactions at 37 °C were performed in 100 mM MES pH 6.5, 5 mM ascorbate, 
2 µM CuSO4, 5000 U bovine catalase, 0.01 (v/v) % Tween 20, 1% (v/v) ethanol, and 20 
µM N-dansyl-Tyr-Val-Gly. The reaction was quenched at desired time with addition of 
trifluoroacetic acid to a final concentration of 2% (v/v).  The product of the reaction N-
dansyl-Tyr-Val-α-hydroxy-Gly was converted to N-dansyl-Tyr-Val-NH2 by incubating 
with potassium hydroxide and 50 mM EDTA to a final pH = 8.5.  Kinetic studies were 
carried out in triplicate. The product was analyzed on HPLC and the initial velocity 
kinetic data analyzed using SigmaPlot.  
 
3. Results and discussion 
 
The hPHMcc gene was inserted into the pET vectors using BamHI and HindIII restriction 
site (Table S2, supplementary material) to generate tagged hPHMcc with a C-terminal 
His6-tag. Soluble hPHMcc-His6 was not achieved by using the GST, Nus A and DscB tag 
in BL 21(DE3), C-41(DE3), and C-43(DE3) E. coli strains even after varying parameters 
like induction temperature, induction time, and addition of Cu(II) and/or PHMcc 
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substrates to the growth media.  In all cases, (except the Trx and MBP tag) hPHMcc was 
produced as inactive and insoluble inclusion bodies.  We were completely unsuccessful 
in generating active PHMcc-His6 after solubilizing and refolding the protein, which had 
been purified from the inclusion bodies.   
 
Soluble and active Trx-hPHMcc-His6 was generated by inserting the hPHMcc gene into 
pET32a(+) vector to yield hPHMcc with a N-terminal Trx fusion and a C-terminal His6-
tag.  Recombinant Trx-hPHMcc-His6 was produced as insoluble inclusion bodies after 
transformation into E. coli BL 21(DE3) with the pET32a(+)-derived vector despite many 
experiments to optimize growth conditions for the generation of soluble protein.  Our 
attempts to solubilize and refold Trx-hPHMcc-His6 or hPHMcc after proteolytic 
separation from Trx and the His6 tag were unsuccessful. 
 
One likely reason for our inability to express active hPHMcc-His6 or Trx-hPHMcc-His6 
in the E. coli BL 21(DE3) cells is relatively high reducing environment of cytoplasm.  
The high cytoplasmic reducing environment inhibits disulfide bond formation, a critical 
factor for the proper folding and activity of PHMcc [30].  We overcame this problem 
with the expression of Trx-hPHMcc-His6 in the Origami B(DE3) strain of E. coli.  The 
cytoplasmic environment of the Origami B(DE3) cells is more oxidizing than that of the 
BL-21 cells due to mutations which inactivate glutathione reductase and thioredoxin 
reductase [34,35].  After optimization (Figure S1, supplementary material), we found that 
soluble Trx-hPHMcc-His6 was expressed at low temperature (10 °C) and a relatively low 
concentration of 100 µM IPTG (Figure 2).  Optimal expression required a short period of 
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IPTG induction (4 hrs) to avoid hPHMcc degradation to lower molecular weight Western 
positive fragments of low activity (data not shown).  
 
During the optimization of expression and purification of Trx-hPHMcc-His6, we 
observed a 65 kDa protein that co-purified with that 52 kDa Trx-hPHMcc-His6.  This 
unknown 65 kDa protein represented 25-30% of the total protein in our samples are 
remained constant using a number of different purification strategies, including size 
exclusion chromatography, ion-exchange chromatography, and affinity chromatography. 
The unknown 65 kDa protein was extracted from the SDS-PAGE gel, digested with 
trypsin, and the tryptic peptides analyzed by LC-MS/MS on a LTQ-orbitrap.  The 65 kDa 
protein was identified as the GroEL-GroES complex, an ATP-dependent molecular 
chaperonin which assists protein folding in bacteria (Horwich et al., 2009). It has been 
proposed that GroEL/GroES/ADP complex binds with non-native protein through 
hydrophobic contacts, followed by protein folding within the GroEL/GroES/ATP cis 
folding chamber [36]. In addition to GroEL-GroES, other chaperonins, such as dnaK, 
dnaJ, grpE, and tig, have been reported to increase the solubility and yield of proteins 
which are difficult to express in bacteria [37].  In order to determine if coexpression of 
hPHMcc with these chaperonins increased the yield of soluble, active enzyme, plasmids 
containing the gene for these chaperonins were inserted in Origami B(DE3) cells which 
already possess the pET32a(+)-hPHMcc-His6 plasmid.  Unfortunately, we found was no 
appreciable increase in the amount of soluble hPHMcc upon coexpression with a 
chaperonin. 
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The GroEL-GroES complex was removed from hPHMcc using a nickel affinity resin.  
The partially purified Trx-hPHMcc-His6 was loaded onto a column packed with Ni-NTA 
resin, the column was washed with guanidine hydrochloride to overcome the interactions 
between Trx-hPHMcc-His6 and the GroEL-GroES complex.  The bound Trx-hPHMcc-
His6 was then eluted from the Ni-NTA resin using a linear, increasing gradient of 
[imidazole].  Trx-hPHMcc-Hi6 was ≥90% homogeneous by SDS-PAGE (Figure 3) and 
Western analysis using an anti-His6 antibody confirmed the presence of the His6 on the 
52.4 kDa Trx-hPHMcc-His6.  The final yield of purified Trx-hPHMcc-His6 was 0.1-0.2 
mg per liter of culture and the purified Trx-hPHMcc-His6 was active.  The steady-state 
kinetic parameters for the Trx-PHMcc-His6 catalyzed oxidation of N-dansyl-Tyr-Val-Gly 
to N-dansyl-Tyr-Val- -hydroxyglycine are as follows: KM = 7.7 ± 0.8 µM, VMAX = 0.40 
± 0.02 µmoles/min/mg, kcat = 0.35 ± 0.02 s
-1
, and kcat/KM = 4.68 ± 0.2 × 10
4 
M
-1
s
-1
 
(Figure 4).  The KM and VMAX values of N-dansyl-Tyr-Val-Gly for rat PHMcc, under 
similar experimental conditions, are reported as 7 µM and 0.5-6 µmoles/min/mg [30], 
which are similar to the values we measured for Trx-hPHMcc-His6.   
 
In other experiments (not shown), we found that both hPHMcc and MBP-PHMcc-His6 
were active when expressed in the E. coli Orgami B (DE3).  The specific activity of 
MBP-PHMcc-His6 was low, (0.12 µmoles/min/mg), and we did no further work with this 
hPHMcc fusion.  We had engineered in thrombin cleavage site C-terminal to Trx and N-
terminal to the His6 tag to enable the thrombinoyltic generation of hPHMcc from Trx-
hPHMcc-His6. Unfortunately, thrombin cleavage of the Trx-hPHMcc-His6 unexpected 
cleaved within hPHMcc generating smaller PHMc-derived fragments. Experiments 
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varying the conditions for the thrombin cleavage of Trx-hPHMcc-His6 always lead to the 
cleavage of hPHMcc and we were unable to completely purify full length hPHMcc away 
from the thrombin-derived fragments.  Because the specific activity of the Trx-hPHMcc-
His6 fusion was in agreement with wildtype rat PHMcc for N-dansyl-Tyr-Val-Gly 
substrate, we did not pursue the expression of hPHMcc in E. coli any further. 
 
4. Conclusion 
 
We report here on the expression of a soluble, active form of the catalytic core of 
hPHMcc in E. coli [30].  The successful production of hPHMcc in E. coli will foster 
future mutagenesis studies to elaborate mechanistic details of PHM catalysis and new 
strategies for the inexpensive production of α-amidated peptides in E. coli.   Co-
expression of glycine-extended peptides and hPHMcc in E. coli, in combination with the 
methods to incorporate non-natural amino acids into α-amidated peptides [38], could 
rapidly lead to novel peptide analogs useful as therapeutics and research tools. 
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Figures: 
 
 
 
 
 
 
Figure 1.  The peptide amidation reaction.  Glycine hydroxylation requires O2, Cu(II), 
and a reductant and is catalyzed by peptidylglycine α-hydroxylating monooxygenase 
(PHM).  Dealkylation of the α-hydroxyglycine-extended peptide requires Zn(II) and 
Ca(II) and is catalyzed by peptidylamidoglycolate lyase (PAL). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Effect of induction temperature (24 
°
C and 10 
°
C) on expression of Trx-
hPHMcc.  Cells were collected at different time interval (0 - 5hrs) after induction and the 
cell lysate was used for the western blot analysis with the anti-PAM antibody.  
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Figure 3. SDS-PAGE Analysis hPHMcc Expression.  Lane-1, molecular weight markers 
(with the molecular weight highlighted inside the bands); lane-2, purified hPHMcc 
inclusion bodies from affinity column; lane-3 purified Trx-hPHMcc with the GroEL-
GroES complex; and lane-4, the purified Trx-PHMcc. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Steady-State Kinetic Analysis of N-Dansyl-Tyr-Val-Gly Hydroxylation. 
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Supplementary Material: 
 
Table S1. 
Properties of the E. coli Strains and Plasmids Employed in Our Studies  
E. coli  Strains Properties 
 BL 21 (DE3) The most common host for protein expression 
F 
–
ompT hsdSB(rB
–
 mB
–
) gal dcm (DE3) 
 C-41 (DE3) Genetically mutated to  increase the tolerance against toxic protein 
F – ompT hsdSB (rB- mB-) gal dcm (DE3) 
 C-43 (DE3) Derived from C-41 (DE3) to express different set of toxic proteins 
F – ompT hsdSB (rB- mB-) gal dcm (DE3) 
 Shuttle T7 
(DE3) 
 
Engineered E. coli strain to promote disulfide bond formation  
fhuA2 lacZ::T7 gene1 [lon] ompT ahpC gal λatt::pNEB3-r1-
cDsbC (Spec
R
, lacI
q
) ΔtrxB sulA11 R(mcr-73::miniTn10--TetS)2 
[dcm] R(zgb-210::Tn10 --Tet
S) endA1 Δgor ∆(mcrC-mrr)114::IS10 
Origami B (DE3) E.coli. strain carries trxB/gor mutation to enhance disulfide bond 
formation 
F
–
ompT hsdSB(rB
–
 mB
–
) gal dcm lacY1 aphC (DE3) gor522::Tn10 
trxB (Kan
R
, Tet
R
) 
Plasmid Vectors Properties 
pET21a(+) C-terminal histidine tag 
pET32a(+) N-terminal thioredoxin tag, helps in catalyzing disulfide bond 
formation in the cytoplasm of trxB mutant 
pET42a(+) N-terminal glutathione-S-transferase (GST) tag to enhance the 
solubility of a target protein 
pET43.1a(+) Incorporates a solubility promoting Nus A tag 
pmal-c2x Maltose binding protein (MBP) fused to the N-terminal of the target 
protein expression  
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Table S2. 
The Expression of hPHMcc in Different Strains of E. coli and Using Different Vectors 
 E. coli Strain
a
 
Vector BL 
21(DE3) 
C-41 (DE3) C-43 
(DE3) 
Origami 
B(DE3) 
T7 Shuttle 
pET21b(+) Inclusion 
Bodies 
Inclusion  
Bodies 
Inclusion  
Bodies 
Inclusion  
Bodies 
Inclusion  
Bodies 
pET32a(+) 
(Trx tag) 
Inclusion 
Bodies 
Inclusion  
Bodies 
Inclusion  
Bodies 
Soluble 
Active  
Enzyme 
Soluble 
Active  
Enzyme 
pET42a(+) 
(GST tag) 
Inclusion 
Bodies 
Inclusion 
Bodies 
Inclusion 
Bodies 
No 
Expression
b 
No 
Expression
b
 
pET43.1a(+) 
(Nus A tag) 
Inclusion 
Bodies 
Inclusion 
Bodies 
Inclusion 
Bodies 
No 
Expression
b
 
No 
Expression
b
 
pET39b(+) 
(DscB tag) 
Inclusion 
Bodies 
Inclusion 
Bodies 
Inclusion 
Bodies 
No 
Expression
b
 
No 
Expression
b
 
pMAL-c2X 
(MBP tag) 
Inclusion 
Bodies 
ND
c
 ND Soluble 
Active  
Enzyme 
ND 
a
E.coli strains were obtained from the following commercial suppliers:  T7 Shuttle (DE3) from New 
England Biolabs, BL 21 (DE3) and Origami B(DE3) from Novagen, (DE3) from New England Biolabs, 
and C-41 (DE3) and C-43 (DE3)from Lucigen.  
b
No western blot positive bands were detected using the anti-PAM antibody.  
c
ND = not done 
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Figure S1. 
Optimization of hPMcc Expression
a
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a
Protein expression was induced at 10 °C under these conditions (1) 0.1mM IPTG, (2) 
0.1mM IPTG and 4 µM Ndansyl-Tyr-Val-Gly, (3) 0.1mM IPTG and 2µM CuSO4, and 
(4) 0.1mM IPTG, 4µM N-dansyl-Tyr-Val-Gly, and 2µM CuSO4. 
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